Hugging Face's logo

Datasets:
FrancophonIA
/
European_Vaccination_Information_Portal

Tasks:
Translation
Languages:
English
Bulgarian
Czech
Dataset card Files Community
European_Vaccination_Information_Portal / data /en-hr.tmx
de-francophones's picture
de-francophones
Upload 23 files
66ba51a verified
raw
history blame contribute delete
233 kB
<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<tmx version="1.4">
<header adminlang="en" creationdate="20200424T153631Z" creationtool="mALIGNa" creationtoolversion="2" datatype="plaintext" o-tmf="al" segtype="block" srclang="hr">
<prop type="distributor">ELRC project</prop>
<prop type="description">Acquisition of bilingual data (from multilingual websites), normalization, cleaning, deduplication and identification of parallel documents have been done by ILSP-FC tool. Maligna aligner was used for alignment of segments. Merging/filtering of segment pairs has also been applied.</prop>
<prop type="l1">hr</prop>
<prop type="l2">en</prop>
<prop type="lengthInTUs">508</prop>
<prop type="# of words in l1">7794</prop>
<prop type="# of words in l2">7465</prop>
<prop type="# of unique words in l1">1524</prop>
<prop type="# of unique words in l2">2292</prop>
</header>
<body>
<tu tuid="1">
<prop type="lengthRatio">1.125</prop>
<tuv xml:lang="en">
<seg>Immunity usually lasts for years, and sometimes for a lifetime.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Imunitet obično traje godinama, a ponekad i čitav život.</seg>
</tuv>
</tu>
<tu tuid="2">
<prop type="lengthRatio">1.125</prop>
<tuv xml:lang="en">
<seg>This is called the antigen.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Njegov je naziv antigen.</seg>
</tuv>
</tu>
<tu tuid="3">
<prop type="lengthRatio">0.8627450980392157</prop>
<tuv xml:lang="en">
<seg>The person is also at risk of complications.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Ta je osoba tada izložena i riziku od komplikacija.</seg>
</tuv>
</tu>
<tu tuid="4">
<prop type="lengthRatio">0.85</prop>
<tuv xml:lang="en">
<seg>How vaccines work</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Kako djeluju cjepiva</seg>
</tuv>
</tu>
<tu tuid="5">
<prop type="lengthRatio">1.2093023255813953</prop>
<tuv xml:lang="en">
<seg>The length of time varies by disease and by vaccine.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Duljina trajanja ovisi o bolesti i cjepivu.</seg>
</tuv>
</tu>
<tu tuid="6">
<prop type="lengthRatio">0.8222222222222222</prop>
<tuv xml:lang="en">
<seg>This ‘ community immunity ' can only work if enough people are vaccinated.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Taj imunitet zajednice može funkcionirati samo onda kada je cijepljen dovoljan broj osoba.</seg>
</tuv>
</tu>
<tu tuid="7">
<prop type="lengthRatio">1.0509554140127388</prop>
<tuv xml:lang="en">
<seg>Vaccines contain a greatly weakened or an inactivated (killed) form of a virus or bacterium that usually causes a disease, or a small part of the virus or bacterium.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Cjepivo sadržava jako oslabljeni ili inaktivirani (mrtvi) oblik virusa ili bakterije koji obično izazivaju bolest ili samo mali dio tog virusa ili bakterije.</seg>
</tuv>
</tu>
<tu tuid="8">
<prop type="lengthRatio">1.1329113924050633</prop>
<tuv xml:lang="en">
<seg>Immunity through vaccination protects not only the immunised individual but also protects unvaccinated people in the community, such as infants who are too young to be vaccinated.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Imunitet koji steknemo cijepljenjem ne štiti samo cijepljenu osobu, već i osobe koje nisu cijepljene u zajednici, poput djece koja su premlada za cijepljenje.</seg>
</tuv>
</tu>
<tu tuid="9">
<prop type="lengthRatio">0.9262672811059908</prop>
<tuv xml:lang="en">
<seg>Each virus and bacterium triggers a unique response in the immune system involving a specific set of cells in the blood, in the bone marrow and all over the body, called T-cells, B-cells, among others.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Svaki virus i svaka bakterija izazivaju jedinstven odgovor imunosnog sustava u koji je uključen određeni skup stanica u krvi, u koštanoj srži i u čitavom tijelu, koje su među ostalim poznate kao T-stanice i B-stanice.</seg>
</tuv>
</tu>
<tu tuid="10">
<prop type="lengthRatio">1.05</prop>
<tuv xml:lang="en">
<seg>Later, if the person comes into contact with the actual infectious virus or bacterium, their immune system will ‘remember' it.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Ako osoba kasnije dođe u kontakt sa stvarnim infektivnim virusom ili bakterijom, njezin će se imunosni sustav „sjetiti".</seg>
</tuv>
</tu>
<tu tuid="11">
<prop type="lengthRatio">1.1226415094339623</prop>
<tuv xml:lang="en">
<seg>A vaccine stimulates an immune response, and a ‘memory' of the body to a specific disease, without causing the disease.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Cjepivo stimulira imunosni odgovor, a tijelo stvara „pamćenje" o određenoj bolesti bez toga da je izazove.</seg>
</tuv>
</tu>
<tu tuid="12">
<prop type="lengthRatio">1.0064102564102564</prop>
<tuv xml:lang="en">
<seg>It will then quickly produce the right antibodies and activate the right immune cells to kill the virus or bacterium, protecting the person from the disease.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Nakon toga vrlo brzo proizvest će protutijela i aktivirati ispravne imunosne stanice koje će uništiti virus ili bakteriju i tako zaštititi osobu od bolesti.</seg>
</tuv>
</tu>
<tu tuid="13">
<prop type="lengthRatio">1.0454545454545454</prop>
<tuv xml:lang="en">
<seg>When a person is given the vaccine, their immune system recognises the antigen as ‘foreign'.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Kada osoba primi cjepivo, njezin imunosni sustav prepoznaje antigen kao „strano tijelo".</seg>
</tuv>
</tu>
<tu tuid="14">
<prop type="lengthRatio">0.9133858267716536</prop>
<tuv xml:lang="en">
<seg>In contrast, a person who becomes immune by getting the disease can expose other unvaccinated people to the disease.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>S druge strane, osoba koja imunitet stekne obolijevanjem može druge osobe koje nisu cijepljene izložiti riziku od obolijevanja.</seg>
</tuv>
</tu>
<tu tuid="15">
<prop type="lengthRatio">0.9578947368421052</prop>
<tuv xml:lang="en">
<seg>The immune cells are trained to kill and make antibodies against the disease-causing agent.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Stanice imunosnog sustava obučene su da uništavaju i stvaraju protutijela za uzročnika bolesti.</seg>
</tuv>
</tu>
<tu tuid="16">
<prop type="lengthRatio">0.8395061728395061</prop>
<tuv xml:lang="en">
<seg>Antibodies are special proteins that help kill the infectious agent.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Protutijela su posebne bjelančevine koje pridonose uništavanju uzročnika bolesti.</seg>
</tuv>
</tu>
<tu tuid="17">
<prop type="lengthRatio">1.9375</prop>
<tuv xml:lang="en">
<seg>Twitter Facebook Linked In Mail</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Sastojci cjepiva</seg>
</tuv>
</tu>
<tu tuid="18">
<prop type="lengthRatio">1.0</prop>
<tuv xml:lang="en">
<seg>Trusted sources</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Pouzdani izvori</seg>
</tuv>
</tu>
<tu tuid="19">
<prop type="lengthRatio">0.9421487603305785</prop>
<tuv xml:lang="en">
<seg>This section provides links to the websites of other health organisations both at national and international level</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Ovaj dio pruža linkove do web stranica drugih zdravstvenih organizacija kako na nacionalnoj tako i na međunarodnoj razini</seg>
</tuv>
</tu>
<tu tuid="20">
<prop type="lengthRatio">0.8863636363636364</prop>
<tuv xml:lang="en">
<seg>European Vaccination Information Portal</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Europski portal za informacije o cijepljenju</seg>
</tuv>
</tu>
<tu tuid="21">
<prop type="lengthRatio">1.1111111111111112</prop>
<tuv xml:lang="en">
<seg>In Europe, influenza occurs...</seg>
</tuv>
<tuv xml:lang="hr">
<seg>U Europi se gripa javlja...</seg>
</tuv>
</tu>
<tu tuid="22">
<prop type="lengthRatio">0.9491525423728814</prop>
<tuv xml:lang="en">
<seg>Vaccines protect people during different stages of life.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Cjepivima se štiti ljude u različitim životnim razdobljima.</seg>
</tuv>
</tu>
<tu tuid="23">
<prop type="lengthRatio">0.7153284671532847</prop>
<tuv xml:lang="en">
<seg>Before a vaccine can be approved in the EU, it has to undergo rigorous testing by its developer...</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Prije nego što se cjepivo može odobriti u EU-u, ono mora biti podvrgnuto strogom ispitivanju koje provodi subjekt koji razvija cjepivo...</seg>
</tuv>
</tu>
<tu tuid="24">
<prop type="lengthRatio">0.9606299212598425</prop>
<tuv xml:lang="en">
<seg>Each virus and bacterium triggers a unique response in the immune system involving a specific set of cells in the blood...</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Svaki virus i svaka bakterija izazivaju jedinstven odgovor imunosnog sustava u koji je uključen određeni skup stanica u krvi...</seg>
</tuv>
</tu>
<tu tuid="25">
<prop type="lengthRatio">1.1625</prop>
<tuv xml:lang="en">
<seg>Vaccination protects individuals against diseases that could have serious consequences for...</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Cijepljenjem se osobe štiti od bolesti koje mogu imati ozbiljne posljedice za...</seg>
</tuv>
</tu>
<tu tuid="26">
<prop type="lengthRatio">1.2</prop>
<tuv xml:lang="en">
<seg>Approval of vaccines in the European Union</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Odobrenje cjepiva u Europskoj uniji</seg>
</tuv>
</tu>
<tu tuid="27">
<prop type="lengthRatio">1.0666666666666667</prop>
<tuv xml:lang="en">
<seg>Influenza (flu) is a contagious respiratory illness caused by infection with an influenza virus.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Gripa (influenca) zarazna je bolest dišnih puteva uzrokovana infekcijom virusom influence.</seg>
</tuv>
</tu>
<tu tuid="28">
<prop type="lengthRatio">1.0404040404040404</prop>
<tuv xml:lang="en">
<seg>Vaccination protects the vaccinated persons and those around them who are vulnerable to the diseases...</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Cijepljenjem se štiti i cijepljene osobe i osobe iz njihova okruženja koje su podložne bolestima...</seg>
</tuv>
</tu>
<tu tuid="29">
<prop type="lengthRatio">1.3076923076923077</prop>
<tuv xml:lang="en">
<seg>When to vaccinate</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Kada cijepiti</seg>
</tuv>
</tu>
<tu tuid="30">
<prop type="lengthRatio">1.1470588235294117</prop>
<tuv xml:lang="en">
<seg>Benefits of vaccination for individuals</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Pojedinačne koristi od cijepljenja</seg>
</tuv>
</tu>
<tu tuid="31">
<prop type="lengthRatio">0.8653846153846154</prop>
<tuv xml:lang="en">
<seg>Vaccines are recommended for different age...</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Cjepiva se preporučuju za različite dobne skupine...</seg>
</tuv>
</tu>
<tu tuid="32">
<prop type="lengthRatio">1.1111111111111112</prop>
<tuv xml:lang="en">
<seg>Read more About us .</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Više o cijepljenju</seg>
</tuv>
</tu>
<tu tuid="33">
<prop type="lengthRatio">1.1714285714285715</prop>
<tuv xml:lang="en">
<seg>Benefits of vaccination for the community</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Koristi od cijepljenja za zajednicu</seg>
</tuv>
</tu>
<tu tuid="34">
<prop type="lengthRatio">1.3717948717948718</prop>
<tuv xml:lang="en">
<seg>Measles is a highly contagious viral disease that can be contracted at any age, and that can spread widely.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Hripavac je vrlo zarazna bakterijska bolest koja zahvaća pluća i dišne putove.</seg>
</tuv>
</tu>
<tu tuid="35">
<prop type="lengthRatio">1.0</prop>
<tuv xml:lang="en">
<seg>About us</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Hripavac</seg>
</tuv>
</tu>
<tu tuid="36">
<prop type="lengthRatio">1.1217391304347826</prop>
<tuv xml:lang="en">
<seg>It typically provides lifelong protection and has an effectiveness of around 97-99% among healthy children who receive two doses.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Ono obično nudi cjeloživotnu zaštitu i djelotvornost mu je oko 97 - 99 % među zdravom djecom koja prime dvije doze.</seg>
</tuv>
</tu>
<tu tuid="37">
<prop type="lengthRatio">0.7166666666666667</prop>
<tuv xml:lang="en">
<seg>They are also less likely to infect others.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Također je manja vjerojatnost da će te osobe zaraziti druge.</seg>
</tuv>
</tu>
<tu tuid="38">
<prop type="lengthRatio">0.7368421052631579</prop>
<tuv xml:lang="en">
<seg>These include:</seg>
</tuv>
<tuv xml:lang="hr">
<seg>U njih se ubrajaju:</seg>
</tuv>
</tu>
<tu tuid="39">
<prop type="lengthRatio">0.889763779527559</prop>
<tuv xml:lang="en">
<seg>Vaccines prevent diseases that could otherwise cause serious health problems, permanent disability or even death.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Cjepivima se sprječavaju bolesti koje bi inače mogle uzrokovati ozbiljne zdravstvene probleme, trajni invaliditet ili čak smrt.</seg>
</tuv>
</tu>
<tu tuid="40">
<prop type="lengthRatio">0.896551724137931</prop>
<tuv xml:lang="en">
<seg>As with any medicine, no vaccine is 100% effective in every person vaccinated.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Kao i drugi lijekovi, nijedno cjepivo nije 100 % djelotvorno za svaku cijepljenu osobu.</seg>
</tuv>
</tu>
<tu tuid="41">
<prop type="lengthRatio">1.0238095238095237</prop>
<tuv xml:lang="en">
<seg>other diseases or conditions they may have;</seg>
</tuv>
<tuv xml:lang="hr">
<seg>druge eventualne bolesti ili druga stanja;</seg>
</tuv>
</tu>
<tu tuid="42">
<prop type="lengthRatio">0.8539325842696629</prop>
<tuv xml:lang="en">
<seg>Individual European countries decide which vaccines should be part of their national vaccination programmes and funded by their national health systems.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Svaka europska zemlja pojedinačno odlučuje o tome koja će cjepiva činiti dio njezina nacionalnog programa cijepljenja i financirati iz sredstava nacionalnih zdravstvenih sustava.</seg>
</tuv>
</tu>
<tu tuid="43">
<prop type="lengthRatio">1.0603448275862069</prop>
<tuv xml:lang="en">
<seg>In some circumstances, a person can still get a disease even after receiving the recommended doses of a vaccine against it.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>U određenim okolnostima osoba se ipak može zaraziti bolešću nakon primanja preporučenih doza cjepiva protiv bolesti.</seg>
</tuv>
</tu>
<tu tuid="44">
<prop type="lengthRatio">1.2653061224489797</prop>
<tuv xml:lang="en">
<seg>Effectiveness in an individual depends on a number of factors.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Pojedinačna djelotvornost ovisi o nizu čimbenika.</seg>
</tuv>
</tu>
<tu tuid="45">
<prop type="lengthRatio">1.0165289256198347</prop>
<tuv xml:lang="en">
<seg>This is due to the person not developing sufficient protection against the disease or due to immunity decreasing over time.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>To se događa jer osoba nije razvila dovoljan stupanj zaštite od bolesti ili zbog toga što je imunitet s vremenom oslabio.</seg>
</tuv>
</tu>
<tu tuid="46">
<prop type="lengthRatio">1.0093457943925233</prop>
<tuv xml:lang="en">
<seg>For example, the vaccine against measles, mumps and rubella (MMR) is highly effective at preventing disease.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Primjerice, cjepivo protiv ospica, zaušnjaka i rubeole (MMR) iznimno je djelotvorno u sprječavanju bolesti.</seg>
</tuv>
</tu>
<tu tuid="47">
<prop type="lengthRatio">1.5</prop>
<tuv xml:lang="en">
<seg>the vaccine.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>cjepivo.</seg>
</tuv>
</tu>
<tu tuid="48">
<prop type="lengthRatio">0.9035532994923858</prop>
<tuv xml:lang="en">
<seg>Once a vaccine is approved for use, EU/EEA national authorities and the European Medicines Agency (EMA), continually monitor side effects in people who have received the vaccine.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Nakon što je cjepivo odobreno za korištenje, nacionalna nadležna tijela u državama EU-a / EGP-a i Europska agencija za lijekove (EMA) kontinuirano prate nuspojave kod osoba koje su primile cjepivo.</seg>
</tuv>
</tu>
<tu tuid="49">
<prop type="lengthRatio">0.9482758620689655</prop>
<tuv xml:lang="en">
<seg>In these cases, however, the person's symptoms are often milder than they would have been without vaccination.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>U tim su slučajevima, međutim, simptomi bolesti često blaži od simptoma koji bi se razvili da nije bilo cijepljenja.</seg>
</tuv>
</tu>
<tu tuid="50">
<prop type="lengthRatio">0.9122807017543859</prop>
<tuv xml:lang="en">
<seg>Monitoring vaccine safety and reporting side effects</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Praćenje sigurnosti cjepiva i izvješćivanje o nuspojavama</seg>
</tuv>
</tu>
<tu tuid="51">
<prop type="lengthRatio">1.0128205128205128</prop>
<tuv xml:lang="en">
<seg>A vaccine's ability to prevent a specific disease determines its effectiveness.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Djelotvornost cjepiva određuje njegova sposobnost da spriječi određenu bolest.</seg>
</tuv>
</tu>
<tu tuid="52">
<prop type="lengthRatio">1.0654205607476634</prop>
<tuv xml:lang="en">
<seg>Authorised vaccines are effective at preventing disease and protecting the population when administered correctly.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Ako se pravilno primjenjuju, odobrena cjepiva djelotvorna su u sprječavanju bolesti i zaštiti stanovništva.</seg>
</tuv>
</tu>
<tu tuid="53">
<prop type="lengthRatio">1.1363636363636365</prop>
<tuv xml:lang="en">
<seg>how the vaccine is given;</seg>
</tuv>
<tuv xml:lang="hr">
<seg>način davanja cjepiva;</seg>
</tuv>
</tu>
<tu tuid="54">
<prop type="lengthRatio">1.2105263157894737</prop>
<tuv xml:lang="en">
<seg>Benefits of vaccinating</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Koristi cijepljenja</seg>
</tuv>
</tu>
<tu tuid="55">
<prop type="lengthRatio">1.0625</prop>
<tuv xml:lang="en">
<seg>previous contact with the disease;</seg>
</tuv>
<tuv xml:lang="hr">
<seg>vrijeme proteklo od cijepljenja;</seg>
</tuv>
</tu>
<tu tuid="56">
<prop type="lengthRatio">0.9642857142857143</prop>
<tuv xml:lang="en">
<seg>National governments take account of factors such as their health systems, legal systems and cultural norms.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Nacionalne vlade uzimaju u obzir čimbenike poput svojih zdravstvenih sustava, pravnih sustava i kulturnih normi.</seg>
</tuv>
</tu>
<tu tuid="57">
<prop type="lengthRatio">1.0285714285714285</prop>
<tuv xml:lang="en">
<seg>Mandatory or recommended vaccination</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Obvezno ili preporučeno cijepljenje</seg>
</tuv>
</tu>
<tu tuid="58">
<prop type="lengthRatio">1.0294117647058822</prop>
<tuv xml:lang="en">
<seg>Vaccination schedules in the EU/EEA</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Rasporedi cijepljenja u EU-u/EGP-u</seg>
</tuv>
</tu>
<tu tuid="59">
<prop type="lengthRatio">1.0065359477124183</prop>
<tuv xml:lang="en">
<seg>In 12 EU/EEA countries, vaccinating children against some diseases is mandatory, although different vaccines are required as mandatory in those countries.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>U 12 država EU-a/EGP-a cijepljenje djece protiv određenih bolesti je obvezno, iako postoje razlike u pogledu toga koja su cjepiva u tim zemljama obvezna.</seg>
</tuv>
</tu>
<tu tuid="60">
<prop type="lengthRatio">0.9393939393939394</prop>
<tuv xml:lang="en">
<seg>Each EU/EEA country implements its own immunisation programme.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Svaka država EU-a/EGP-a provodi svoj vlastiti program imunizacije.</seg>
</tuv>
</tu>
<tu tuid="61">
<prop type="lengthRatio">0.7678571428571429</prop>
<tuv xml:lang="en">
<seg>Each EU/EEA country decides if vaccination is mandatory or voluntary in its territory.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Svaka država EU-a/EGP-a odlučuje o tome je li cijepljenje obvezno ili dobrovoljno na njezinom državnom području.</seg>
</tuv>
</tu>
<tu tuid="62">
<prop type="lengthRatio">1.0104166666666667</prop>
<tuv xml:lang="en">
<seg>Information on which countries have mandatory vaccination can be found in the Vaccine Scheduler .</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Informacije o tome u kojim je državama cijepljenje obvezno možete pronaći urasporedu cijepljenja</seg>
</tuv>
</tu>
<tu tuid="63">
<prop type="lengthRatio">1.05</prop>
<tuv xml:lang="en">
<seg>Most EU/EEA countries offer vaccination on a recommended basis.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Većina država EU-a/EGP-a nudi cijepljenje na bazi preporuke.</seg>
</tuv>
</tu>
<tu tuid="64">
<prop type="lengthRatio">1.168421052631579</prop>
<tuv xml:lang="en">
<seg>EU/EEA countries have achieved high vaccination coverage rates through mandatory and non-mandatory vaccination.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Države EU-a/EGP-a postigle su obveznim i neobveznim cijepljenjem visoke stope procijepljenosti.</seg>
</tuv>
</tu>
<tu tuid="65">
<prop type="lengthRatio">1.0952380952380953</prop>
<tuv xml:lang="en">
<seg>This is offered to women in accordance with national recommendations.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Postupak je dostupan ženama u skladu s nacionalnim preporukama.</seg>
</tuv>
</tu>
<tu tuid="66">
<prop type="lengthRatio">0.9292035398230089</prop>
<tuv xml:lang="en">
<seg>For more information check the ECDC website: https://www.ecdc.europa.eu/en/human-papillomavirus/factsheet</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Više informacija potražite na mrežnom mjestu ECDC-a: https://www.ecdc.europa.eu/en/human-papillomavirus/factsheet</seg>
</tuv>
</tu>
<tu tuid="67">
<prop type="lengthRatio">1.088235294117647</prop>
<tuv xml:lang="en">
<seg>If HPV does not go away it may cause:</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Ako HPV ne nestane, može izazvati:</seg>
</tuv>
</tu>
<tu tuid="68">
<prop type="lengthRatio">1.05</prop>
<tuv xml:lang="en">
<seg>It is the most common sexually transmitted infection worldwide.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Riječ je o najčešćoj spolno prenosivoj infekciji na svijetu.</seg>
</tuv>
</tu>
<tu tuid="69">
<prop type="lengthRatio">0.8913043478260869</prop>
<tuv xml:lang="en">
<seg>About 40 of them can infect the genitals.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Oko 40 njih može izazvati genitalne infekcije.</seg>
</tuv>
</tu>
<tu tuid="70">
<prop type="lengthRatio">1.0454545454545454</prop>
<tuv xml:lang="en">
<seg>There is no treatment for the virus itself, but the health problems caused by HPV can be treated in different ways.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Ne postoji lijek za sami virus, ali zdravstveni problemi izazvani HPV-om mogu se liječiti na različite načine.</seg>
</tuv>
</tu>
<tu tuid="71">
<prop type="lengthRatio">1.0510204081632653</prop>
<tuv xml:lang="en">
<seg>In most cases, an HPV infection disappears on its own without causing any obvious symptoms or problems.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>U većini slučajeva infekcija HPV-om nestaje sama od sebe i ne izaziva očite simptome ili probleme.</seg>
</tuv>
</tu>
<tu tuid="72">
<prop type="lengthRatio">1.103448275862069</prop>
<tuv xml:lang="en">
<seg>Routine HPV vaccination usually takes place between 9 and 14 years of age, in accordance with the national vaccination schedule.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Rutinsko cijepljenje protiv HPV-a obavlja se u dobi od 9 do 14 godina, u skladu s nacionalnim programom cijepljenja.</seg>
</tuv>
</tu>
<tu tuid="73">
<prop type="lengthRatio">0.8712121212121212</prop>
<tuv xml:lang="en">
<seg>However, sometimes the HPV infection can persist and cause after some years some of the complications listed below.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Međutim, infekcije HPV-om ponekad mogu biti tvrdokorne i izazvati, nakon nekoliko godina, neke od komplikacija navedenih u nastavku.</seg>
</tuv>
</tu>
<tu tuid="74">
<prop type="lengthRatio">0.9183673469387755</prop>
<tuv xml:lang="en">
<seg>There are more than 100 types of HPV viruses.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Postoji više od 100 vrsta humanih papilomavirusa.</seg>
</tuv>
</tu>
<tu tuid="75">
<prop type="lengthRatio">1.0225563909774436</prop>
<tuv xml:lang="en">
<seg>Human papillomavirus (HPV) infection is a viral infection that is mainly sexually transmitted by direct contact with an infected person.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Infekcija humanim papilomavirusom (HPV) virusna je infekcija koja se uglavnom prenosi izravnim spolnim kontaktom sa zaraženom osobom.</seg>
</tuv>
</tu>
<tu tuid="76">
<prop type="lengthRatio">0.8650306748466258</prop>
<tuv xml:lang="en">
<seg>Other HPV-related cancers are also more treatable when diagnosed and treated early, but there are no specific screening programmes for these.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>I liječenje drugih vrsta raka povezanih s HPV-om uspješnije je ako se bolest dijagnosticira i liječi u ranoj fazi, ali za njih ne postoje posebni programi probira.</seg>
</tuv>
</tu>
<tu tuid="77">
<prop type="lengthRatio">0.9767441860465116</prop>
<tuv xml:lang="en">
<seg>HPV is transmitted by direct contact, mainly sexual, with someone who has the virus.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>HPV se prenosi izravnim kontaktom, uglavnom spolnim, s osobom koja je nositelj virusa.</seg>
</tuv>
</tu>
<tu tuid="78">
<prop type="lengthRatio">0.8787878787878788</prop>
<tuv xml:lang="en">
<seg>A healthcare provider should be consulted for advice on the specific treatment options.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Za savjet o specifičnim mogućnostima liječenja potrebno se obratiti pružatelju zdravstvene zaštite.</seg>
</tuv>
</tu>
<tu tuid="79">
<prop type="lengthRatio">0.8607594936708861</prop>
<tuv xml:lang="en">
<seg>Vaccination of girls and boys against HPV can prevent HPV infections and consequently HPV-related diseases in both sexes, including genital and anal warts, cervical cancer and other cancers caused by HPV.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Cijepljenjem dječaka i djevojčica protiv HPV-a mogu se spriječiti infekcije HPV-om i, posljedično, bolesti povezane s HPV-om u oba spola, kao što su genitalne i analne bradavice, rak grlića maternice i druge vrste raka uzrokovane HPV-om.</seg>
</tuv>
</tu>
<tu tuid="80">
<prop type="lengthRatio">0.6666666666666666</prop>
<tuv xml:lang="en">
<seg>Genital warts can be treated using medication or by surgery.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Ako je riječ o genitalnim bradavicama, mogu se primijeniti lijekovi ili kirurški postupak.</seg>
</tuv>
</tu>
<tu tuid="81">
<prop type="lengthRatio">0.8145161290322581</prop>
<tuv xml:lang="en">
<seg>At least 14 HPV types, classified as ‘high risk', can cause cancer, such as cervical cancer in women.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Najmanje 14 vrsta HPV-a pripada u skupinu „visokorizičnih" jer mogu prouzročiti rak, kao što je rak grlića maternice u žena.</seg>
</tuv>
</tu>
<tu tuid="82">
<prop type="lengthRatio">0.9375</prop>
<tuv xml:lang="en">
<seg>Anyone who is sexually active is at risk of contracting HPV.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Sve spolno aktivne osobe izložene su riziku od infekcije HPV-om.</seg>
</tuv>
</tu>
<tu tuid="83">
<prop type="lengthRatio">0.9655172413793104</prop>
<tuv xml:lang="en">
<seg>cervical or other types of cancer (e.g. vulvar, vaginal, anal penile, and some cancers of the head and the neck)</seg>
</tuv>
<tuv xml:lang="hr">
<seg>rak grlića maternice ili druge vrste raka (npr. rak stidnice, rodnice, anusa, penisa i neke vrste raka glave i vrata</seg>
</tuv>
</tu>
<tu tuid="84">
<prop type="lengthRatio">0.8529411764705882</prop>
<tuv xml:lang="en">
<seg>What are the symptoms of HPV?</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Koji su simptomi infekcije HPV-om?</seg>
</tuv>
</tu>
<tu tuid="85">
<prop type="lengthRatio">1.0</prop>
<tuv xml:lang="en">
<seg>How is HPV treated?</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Kako se HPV liječi?</seg>
</tuv>
</tu>
<tu tuid="86">
<prop type="lengthRatio">1.3867924528301887</prop>
<tuv xml:lang="en">
<seg>Cervical cancer and tissue in the cervix that is described as ‘precancerous' can be identified early through cervical cancer screening and treated.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Rak i pretkancerogeno tkivo u području grlića maternice moguće je rano otkriti metodom probira i liječiti.</seg>
</tuv>
</tu>
<tu tuid="87">
<prop type="lengthRatio">0.7857142857142857</prop>
<tuv xml:lang="en">
<seg>genital and anal warts</seg>
</tuv>
<tuv xml:lang="hr">
<seg>genitalne i analne bradavice</seg>
</tuv>
</tu>
<tu tuid="88">
<prop type="lengthRatio">0.7096774193548387</prop>
<tuv xml:lang="en">
<seg>Who is at risk of HPV?</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Tko je izložen riziku od HPV-a?</seg>
</tuv>
</tu>
<tu tuid="89">
<prop type="lengthRatio">0.6097560975609756</prop>
<tuv xml:lang="en">
<seg>How can HPV be prevented?</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Kako se infekcija HPV-om može spriječiti?</seg>
</tuv>
</tu>
<tu tuid="90">
<prop type="lengthRatio">0.5604395604395604</prop>
<tuv xml:lang="en">
<seg>This is because HPV can also occasionally infect surrounding skin that is not protected by the condom.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Upotreba prezervativa nije 100 % djelotvorna u pogledu sprječavanja prijenosa virusa. zbog toga što HPV-om ponekad može biti zaražena i okolna koža koja nije zaštićena prezervativom.</seg>
</tuv>
</tu>
<tu tuid="91">
<prop type="lengthRatio">0.7727272727272727</prop>
<tuv xml:lang="en">
<seg>What are the complications of HPV?</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Koje su moguće komplikacije izazvane HPV-om?</seg>
</tuv>
</tu>
<tu tuid="92">
<prop type="lengthRatio">0.7160493827160493</prop>
<tuv xml:lang="en">
<seg>The 'low risk' HPV types can cause genital and anal warts.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>„Niskorizične" vrste HPV-a mogu dovesti do pojave genitalnih i analnih bradavica.</seg>
</tuv>
</tu>
<tu tuid="93">
<prop type="lengthRatio">0.5725806451612904</prop>
<tuv xml:lang="en">
<seg>Cervical cancer (cancer of the neck of the womb) is the most common cancer after breast cancer to affect women aged 15-44 years in Europe (1).</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Rak grlića maternice najčešća je vrsta raka, nakon raka dojke, od koje obolijevaju žene u Europi u dobi od 15 do 44 godine (1). „Visokorizične" vrste HPV-a mogu uzrokovati i rak anusa i genitalija te neke vrste raka glave i vrata, neovisno o spolu.</seg>
</tuv>
</tu>
<tu tuid="94">
<prop type="lengthRatio">0.9565217391304348</prop>
<tuv xml:lang="en">
<seg>It can spread quickly.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Može se brzo proširiti.</seg>
</tuv>
</tu>
<tu tuid="95">
<prop type="lengthRatio">1.0</prop>
<tuv xml:lang="en">
<seg>Less than 5% will have fever.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Manje od 5 % imat će vrućicu.</seg>
</tuv>
</tu>
<tu tuid="96">
<prop type="lengthRatio">0.96875</prop>
<tuv xml:lang="en">
<seg>Measles had almost been eliminated in many European countries.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Ospice su bile gotovo iskorijenjene u mnogim europskim zemljama.</seg>
</tuv>
</tu>
<tu tuid="97">
<prop type="lengthRatio">1.45</prop>
<tuv xml:lang="en">
<seg>Therefore, the long-term benefits of getting vaccinated may not be immediately obvious.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Stoga dugotrajne koristi cijepljenja možda nisu odmah očite.</seg>
</tuv>
</tu>
<tu tuid="98">
<prop type="lengthRatio">1.1297709923664123</prop>
<tuv xml:lang="en">
<seg>It will often lead to hospitalisation in infants, and the risk of complications and hospitalisation increases for infants younger than three months.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Djecu se zbog njega često mora hospitalizirati, a opasnost od komplikacija i hospitalizacije veća je za djecu mlađu od tri mjeseca.</seg>
</tuv>
</tu>
<tu tuid="99">
<prop type="lengthRatio">0.8952380952380953</prop>
<tuv xml:lang="en">
<seg>If people stopped being vaccinated, many of these diseases and related outbreaks could return.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Ako bi se ljudi prestali cijepiti, mnoge od tih bolesti i s njima povezane epidemije mogle bi se vratiti.</seg>
</tuv>
</tu>
<tu tuid="100">
<prop type="lengthRatio">0.9125</prop>
<tuv xml:lang="en">
<seg>It can cause severe spasms of cough and usually lasts three to six weeks.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Hripavac može izazvati teške napadaje kašlja i obično traje tri do šest tjedana.</seg>
</tuv>
</tu>
<tu tuid="101">
<prop type="lengthRatio">1.0194174757281553</prop>
<tuv xml:lang="en">
<seg>Vaccines are used in hundreds of millions of people worldwide each year to protect from serious diseases.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Stotine milijuna ljudi diljem svijeta svake se godine cijepi kako bi se zaštitili od ozbiljnih bolesti.</seg>
</tuv>
</tu>
<tu tuid="102">
<prop type="lengthRatio">1.0379746835443038</prop>
<tuv xml:lang="en">
<seg>However, since October 2016 a resurgence of measles has been observed in the EU/EEA, with outbreaks in several countries (2), due to a decline in vaccination rates.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Međutim, od listopada 2016. uočena je ponovna pojava ospica u EU-u/EGP-u uz epidemije u nekoliko zemalja (2), što je povezano sa smanjenom stopom cijepljenja.</seg>
</tuv>
</tu>
<tu tuid="103">
<prop type="lengthRatio">0.9210526315789473</prop>
<tuv xml:lang="en">
<seg>About 20% of infants will have redness and pain at the injection site.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Oko 20 % djece imat će crvenilo i osjećati bol na mjestu primjene injekcije.</seg>
</tuv>
</tu>
<tu tuid="104">
<prop type="lengthRatio">1.096774193548387</prop>
<tuv xml:lang="en">
<seg>For example, during 2018 about 86% of infants worldwide received three doses of the vaccine that protects them against diphtheria, tetanus and pertussis (DTP), and 85% of infants around the world received three doses of polio vaccine (1).</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Na primjer, tijekom 2018. oko 86 % male djece diljem svijeta primilo je tri doze cjepiva za zaštitu od difterije, tetanusa i hripavca (cjepivo DTP), a 85 % djece primilo je tri doze cjepiva protiv dječje paralize (1).</seg>
</tuv>
</tu>
<tu tuid="105">
<prop type="lengthRatio">1.12</prop>
<tuv xml:lang="en">
<seg>Vaccination against pertussis is part of national immunisation programmes in the EU.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Cijepljenje protiv hripavca dio je nacionalnih programa cijepljenja u EU-u.</seg>
</tuv>
</tu>
<tu tuid="106">
<prop type="lengthRatio">1.0296296296296297</prop>
<tuv xml:lang="en">
<seg>Many infectious diseases are very rare today thanks to vaccination, so the negative consequences of these diseases are sometimes forgotten.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Zahvaljujući cijepljenju mnoge su zarazne bolesti danas vrlo rijetke, tako da se ponekad zaboravljaju negativne posljedice tih bolesti.</seg>
</tuv>
</tu>
<tu tuid="107">
<prop type="lengthRatio">0.9318181818181818</prop>
<tuv xml:lang="en">
<seg>Unlike a treatment given to cure an illness, vaccines are usually given to healthy people to prevent them from getting ill.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Za razliku od terapije koja se daje za liječenje bolesti, cjepiva se obično daju zdravim ljudima kako bi ih se zaštitilo od bolesti.</seg>
</tuv>
</tu>
<tu tuid="108">
<prop type="lengthRatio">1.0303030303030303</prop>
<tuv xml:lang="en">
<seg>Complications can include pneumonia, encephalopathy (a disease of the brain), seizures and even death.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Komplikacije mogu uključivati upalu pluća, encefalopatiju (bolest mozga), konvulzije pa čak i smrt.</seg>
</tuv>
</tu>
<tu tuid="109">
<prop type="lengthRatio">0.96</prop>
<tuv xml:lang="en">
<seg>Measles can be serious or even life-threatening.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Ospice mogu biti ozbiljne ili čak opasne po život.</seg>
</tuv>
</tu>
<tu tuid="110">
<prop type="lengthRatio">1.1590909090909092</prop>
<tuv xml:lang="en">
<seg>The only protection against measles is vaccination.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Jedina zaštita protiv ospica je cijepljenje.</seg>
</tuv>
</tu>
<tu tuid="111">
<prop type="lengthRatio">1.3571428571428572</prop>
<tuv xml:lang="en">
<seg>The MMR vaccine is safe and effective.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Ono je sigurno i učinkovito.</seg>
</tuv>
</tu>
<tu tuid="112">
<prop type="lengthRatio">1.2833333333333334</prop>
<tuv xml:lang="en">
<seg>The MMR vaccine protects against measles, mumps and rubella (German measles).</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Cjepivo MMR štiti od ospica, zaušnjaka i rubeole (crljenca).</seg>
</tuv>
</tu>
<tu tuid="113">
<prop type="lengthRatio">0.6923076923076923</prop>
<tuv xml:lang="en">
<seg>For more information, see measles factsheet .</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Za dodatne informacije pogledajte informativni sažetak o hripavcu</seg>
</tuv>
</tu>
<tu tuid="114">
<prop type="lengthRatio">0.7230769230769231</prop>
<tuv xml:lang="en">
<seg>For more information, see pertussis factsheet .</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Za dodatne informacije pogledajte informativni sažetak o ospicama</seg>
</tuv>
</tu>
<tu tuid="115">
<prop type="lengthRatio">0.9841269841269841</prop>
<tuv xml:lang="en">
<seg>Pertussis (whooping cough) is a disease affecting the airways.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Hripavac (magareći kašalj) je bolest koja zahvaća dišne puteve.</seg>
</tuv>
</tu>
<tu tuid="116">
<prop type="lengthRatio">1.5555555555555556</prop>
<tuv xml:lang="en">
<seg>This protects children from whooping cough, while it only causes minor side effects.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Time se djeca štite od hripavca, a nuspojave su blage.</seg>
</tuv>
</tu>
<tu tuid="117">
<prop type="lengthRatio">1.8235294117647058</prop>
<tuv xml:lang="en">
<seg>Twitter Facebook Linked In Mail</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Primjer: hripavac</seg>
</tuv>
</tu>
<tu tuid="118">
<prop type="lengthRatio">1.224770642201835</prop>
<tuv xml:lang="en">
<seg>Factors driving such differences may include the disease's burden, prevalence of the disease and trends in different countries, the resources and structures of healthcare systems, political and cultural factors, as well as the resilience of the vaccination programme.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Razlozi za te razlike mogu uključivati teret bolesti, njenu pojavnost i trendove u različitim zemljama, resurse i strukture zdravstvenih sustava, političke i kulturološke čimbenike kao i otpornost programa cijepljenja.</seg>
</tuv>
</tu>
<tu tuid="119">
<prop type="lengthRatio">1.0845588235294117</prop>
<tuv xml:lang="en">
<seg>These may include the age and population to be vaccinated (for example, all children of a certain age or only those in a risk group), the exact type of vaccine (e.g. some ingredients may differ), the number and timing of doses, and whether a vaccine is given alone or in combination with others.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Te se razlike mogu odnositi na dob i skupine koje treba cijepiti (na primjer, sva djeca ili samo ona iz rizične skupine), određeni tip cjepiva (neki se sastojci mogu razlikovati), broj i raspored doza te primjenjuje li se cjepivo samo ili u kombinaciji s drugim cjepivima.</seg>
</tuv>
</tu>
<tu tuid="120">
<prop type="lengthRatio">0.9612903225806452</prop>
<tuv xml:lang="en">
<seg>Each EU/EEA country is responsible for its own national public health policy, including its national immunisation programme and vaccination schedule.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Svaka država EU-a / EGP-a odgovorna je za svoju nacionalnu politiku javnog zdravstva, uključujući za nacionalni program cijepljenja i raspored cijepljenja.</seg>
</tuv>
</tu>
<tu tuid="121">
<prop type="lengthRatio">1.0555555555555556</prop>
<tuv xml:lang="en">
<seg>There are some differences in the way countries organise their vaccination schedules, which are similar but not identical in different EU/EEA countries.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Postoje neke razlike u organizaciji rasporeda cijepljenja među zemljama, koji su slični, ali ne i posve isti u različitim državama EU-a / EGP-a.</seg>
</tuv>
</tu>
<tu tuid="122">
<prop type="lengthRatio">1.0327868852459017</prop>
<tuv xml:lang="en">
<seg>The same level of protection is ensured in each EU/EEA country.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Ista razina zaštite osigurana je u svim zemljama EU-a / EGP-a</seg>
</tuv>
</tu>
<tu tuid="123">
<prop type="lengthRatio">1.1219512195121952</prop>
<tuv xml:lang="en">
<seg>The childhood vaccination schedules in all EU/EEA countries include the vaccination against:</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Rasporedi cijepljenja djece u svim državama EU-a / EGP-a uključuju cjepiva protiv:</seg>
</tuv>
</tu>
<tu tuid="124">
<prop type="lengthRatio">0.9130434782608695</prop>
<tuv xml:lang="en">
<seg>Vaccines in the national schedules are given in the appropriate timeframes to ensure adequate protection.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Za osiguranje odgovarajuće zaštite, cjepiva se u nacionalnim rasporedima daju u odgovarajućim vremenskim razmacima.</seg>
</tuv>
</tu>
<tu tuid="125">
<prop type="lengthRatio">0.65</prop>
<tuv xml:lang="en">
<seg>The differences between vaccination schedules do not mean that some are better than others.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Razlike među rasporedima cijepljenja ne znače da su neki bolji od drugih, samo se uzimaju u obzir različite okolnosti i zdravstvene sustave.</seg>
</tuv>
</tu>
<tu tuid="126">
<prop type="lengthRatio">1.008849557522124</prop>
<tuv xml:lang="en">
<seg>Information on the national vaccination schedules in EU/EEA countries can be found in the ECDC Vaccine Scheduler .</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Podatci o nacionalnim rasporedima cijepljenja u državama EU-a / EGP-a nalaze se u ECDC-ovom rasporedu cijepljenja</seg>
</tuv>
</tu>
<tu tuid="127">
<prop type="lengthRatio">1.0434782608695652</prop>
<tuv xml:lang="en">
<seg>They can still catch up.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>To se može nadoknaditi.</seg>
</tuv>
</tu>
<tu tuid="128">
<prop type="lengthRatio">1.0113636363636365</prop>
<tuv xml:lang="en">
<seg>Some people may have missed a vaccination or did not get the recommended number of doses.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Neki su ljudi možda propustili jedno cijepljenje ili nisu primili preporučeni broj doza.</seg>
</tuv>
</tu>
<tu tuid="129">
<prop type="lengthRatio">0.7017543859649122</prop>
<tuv xml:lang="en">
<seg>Most vaccines provide lifelong immunity.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Većina cjepiva osigurava imunitet tijekom cijelog života.</seg>
</tuv>
</tu>
<tu tuid="130">
<prop type="lengthRatio">1.2374100719424461</prop>
<tuv xml:lang="en">
<seg>If a person does not know if they have been vaccinated against a certain disease they can usually get an extra dose without increasing the risk of serious side effects (1).</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Ako netko ne zna je li cijepljen protiv određene bolesti, obično može primiti dodatnu dozu bez povećanog rizika od ozbiljnih nuspojava (1).</seg>
</tuv>
</tu>
<tu tuid="131">
<prop type="lengthRatio">0.8532110091743119</prop>
<tuv xml:lang="en">
<seg>However, some vaccines provide immunity that decreases over time, known as ‘waning immunity'.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Međutim, neka cjepiva pružaju imunitet koji se s vremenom smanjuje, poznat pod nazivom „imunitet koji slabi".</seg>
</tuv>
</tu>
<tu tuid="132">
<prop type="lengthRatio">0.9932885906040269</prop>
<tuv xml:lang="en">
<seg>Everyone should check if they have had the nationally recommended vaccinations, and consult a medical professional in case any catch-ups are needed.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Svatko bi trebao provjeriti je li primio cjepiva preporučena na nacionalnoj razini i savjetovati se s liječnikom ako su mu potrebna naknadna cjepiva.</seg>
</tuv>
</tu>
<tu tuid="133">
<prop type="lengthRatio">0.9416058394160584</prop>
<tuv xml:lang="en">
<seg>For some diseases, such as varicella (chickenpox) and rubella, it is also possible to do a test to check if the person is immune.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Kod nekih bolesti, poput vodenih kozica (varicelle) i rubeole postoji test kojim se može provjeriti je li osoba na njih razvila imunitet.</seg>
</tuv>
</tu>
<tu tuid="134">
<prop type="lengthRatio">0.8918918918918919</prop>
<tuv xml:lang="en">
<seg>Catch-up vaccination and boosters</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Naknadna cijepljenja i docjepljivanje</seg>
</tuv>
</tu>
<tu tuid="135">
<prop type="lengthRatio">1.1326530612244898</prop>
<tuv xml:lang="en">
<seg>This may involve looking at vaccination records or the vaccination schedules in place when the person was born.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>To može podrazumijevati provjeru knjižica ili rasporeda cijepljenja u mjestu gdje je osoba rođena.</seg>
</tuv>
</tu>
<tu tuid="136">
<prop type="lengthRatio">0.9942857142857143</prop>
<tuv xml:lang="en">
<seg>Some countries recommend booster doses at regular intervals during adolescence and adulthood, in order to maintain immunity over a longer period of time, against for example:</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Neke zemlje preporučuju docjepljivanje u redovnim razmacima tijekom puberteta i u odrasloj dobi kako bi se imunitet dulje vrijeme održao protiv bolesti kao što su, na primjer:</seg>
</tuv>
</tu>
<tu tuid="137">
<prop type="lengthRatio">1.011070110701107</prop>
<tuv xml:lang="en">
<seg>For example, due to an increasing number of measles cases among teenagers and young adults, catch-up programmes exist in a number of EU/EEA countries for people who may have missed the measles vaccination when they were younger or are too old to have received it as a child.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Na primjer, zbog sve veće pojavnosti ospica među tinejdžerima i mlađim odraslim osobama u brojim zemljama EU-a / EGP-a dostupni su programi naknadnog cijepljenja za osobe koje nisu cijepljene protiv ospica u djetinjstvu ili im to cjepivo u djetinjstvu nije bilo dostupno.</seg>
</tuv>
</tu>
<tu tuid="138">
<prop type="lengthRatio">0.9594594594594594</prop>
<tuv xml:lang="en">
<seg>Catch-up vaccination programmes for specific diseases may be organised.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Za određene bolesti moguće je organizirati programe naknadnog cijepljenja.</seg>
</tuv>
</tu>
<tu tuid="139">
<prop type="lengthRatio">0.91</prop>
<tuv xml:lang="en">
<seg>For example, tetanus can be encountered due to common injuries, including dog or cat bites.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Na primjer, tetanus se može razviti zbog uobičajenih ozljeda, uključujući od ugriza pasa ili mačaka.</seg>
</tuv>
</tu>
<tu tuid="140">
<prop type="lengthRatio">1.2666666666666666</prop>
<tuv xml:lang="en">
<seg>This is known as 'community immunity' (also referred to as 'herd immunity').</seg>
</tuv>
<tuv xml:lang="hr">
<seg>To se zove „kolektivni imunitet" (ili „imunitet zajednice").</seg>
</tuv>
</tu>
<tu tuid="141">
<prop type="lengthRatio">1.1300448430493273</prop>
<tuv xml:lang="en">
<seg>For example, to ensure community immunity against measles, public health authorities recommend that 95% of the population are vaccinated with two doses of the vaccine against measles (the MMR vaccine, which protects against measles, mumps and rubella).</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Na primjer, da bi se u zajednici osigurala imunost na ospice, zavodi za javno zdravstvo preporučuju da se 95 % stanovništva cijepi s dvije doze cjepiva protiv ospica (cjepivom MMR koje štiti od ospica, zaušnjaka i rubeole).</seg>
</tuv>
</tu>
<tu tuid="142">
<prop type="lengthRatio">0.9755244755244755</prop>
<tuv xml:lang="en">
<seg>Furthermore, immunisation programmes help reduce the social, psychological and financial burdens of disease on people and governments, reducing pressures on healthcare and social care systems and enabling people to pursue productive activities including education and employment.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Nadalje, programi cijepljenja pomažu u smanjenju socijalnih, psiholoških i financijskih tereta od bolesti na pojedince i državu, uključujući manji pritisak na sustave zdravstva i socijalne skrbi te omogućavajući ljudima da se bave produktivnim aktivnostima kao što su obrazovanje i rad.</seg>
</tuv>
</tu>
<tu tuid="143">
<prop type="lengthRatio">1.0165289256198347</prop>
<tuv xml:lang="en">
<seg>Vaccination protects the vaccinated persons and those around them who are vulnerable to the diseases, reducing the risk of diseases spreading among family members, school mates or colleagues, friends, neighbours and other people in the community.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Cijepljenjem se štiti i cijepljene osobe i osobe iz njihova okruženja koje su podložne bolestima, čime se smanjuje rizik od širenja bolesti među članovima obitelji, učenicima ili kolegama, prijateljima, susjedima i drugim ljudima u zajednici.</seg>
</tuv>
</tu>
<tu tuid="144">
<prop type="lengthRatio">1.0092592592592593</prop>
<tuv xml:lang="en">
<seg>It means that people who cannot be vaccinated, for instance because they are too young or allergic to vaccine components, benefit from others being vaccinated, because the disease cannot easily spread in the community.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>To znači da su osobe koje se ne mogu cijepiti, na primjer zato što su premlade ili alergične na sastojke cjepiva, djelomično zaštićene jer su ljudi oko njih cijepljeni te se bolest ne može lako proširiti u zajednici.</seg>
</tuv>
</tu>
<tu tuid="145">
<prop type="lengthRatio">1.0066666666666666</prop>
<tuv xml:lang="en">
<seg>These include babies, children, the elderly, people with weak immune systems, cancer patients, and people who cannot be vaccinated for medical reasons.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Podložne osobe su bebe, djeca, stariji ljudi, osobe sa slabim imunitetom, oboljeli od raka i osobe koje se zbog medicinskih razloga ne smiju cijepiti.</seg>
</tuv>
</tu>
<tu tuid="146">
<prop type="lengthRatio">1.1367521367521367</prop>
<tuv xml:lang="en">
<seg>When enough people in a population are immune to an infectious disease, the disease is then unlikely to spread from person to person.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Kada je dovoljan broj osoba imun na zarazne bolesti, mala je vjerojatnost da će se bolest prenositi s osobe na osobu.</seg>
</tuv>
</tu>
<tu tuid="147">
<prop type="lengthRatio">1.0833333333333333</prop>
<tuv xml:lang="en">
<seg>In this way, vaccines indirectly protect others who are vulnerable to disease.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Na taj se način cjepivom neizravno štiti i druge osobe podložne bolesti.</seg>
</tuv>
</tu>
<tu tuid="148">
<prop type="lengthRatio">1.2857142857142858</prop>
<tuv xml:lang="en">
<seg>Vaccination is the only way to ensure direct protection against tetanus.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Izravna zaštita od tetanusa moguća je samo cijepljenjem.</seg>
</tuv>
</tu>
<tu tuid="149">
<prop type="lengthRatio">1.103448275862069</prop>
<tuv xml:lang="en">
<seg>Community immunity occurs when enough people in a population are immune to an infectious disease</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Kolektivni imunitet postiže se kad je dovoljan broj stanovnika imun na zarazne bolesti.</seg>
</tuv>
</tu>
<tu tuid="150">
<prop type="lengthRatio">0.9186046511627907</prop>
<tuv xml:lang="en">
<seg>However, people cannot rely on community immunity for some infectious diseases.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Međutim, kod nekih zaraznih bolesti ljudi se ne mogu oslanjati na kolektivni imunitet.</seg>
</tuv>
</tu>
<tu tuid="151">
<prop type="lengthRatio">1.0625</prop>
<tuv xml:lang="en">
<seg>When looking at health-related information, it can be difficult to judge the quality and accuracy of information found.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Pri razmatranju zdravstvenih informacija može biti teško procijeniti kvalitetu i točnost pronađenih informacija.</seg>
</tuv>
</tu>
<tu tuid="152">
<prop type="lengthRatio">0.86</prop>
<tuv xml:lang="en">
<seg>Official websites from EU and EEA countries</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Službena mrežna mjesta država članica EU-a i EGP-a</seg>
</tuv>
</tu>
<tu tuid="153">
<prop type="lengthRatio">1.2027027027027026</prop>
<tuv xml:lang="en">
<seg>People may wonder where to find accurate information, who is behind the development of the information they find, and also if the information is supported by scientific evidence.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Mogu se pitati gdje pronaći točne informacije, tko stoji iza informacija koje pronađu te jesu li te informacije potkrijepljene znanstvenim dokazima.</seg>
</tuv>
</tu>
<tu tuid="154">
<prop type="lengthRatio">1.0125786163522013</prop>
<tuv xml:lang="en">
<seg>The Vaccine Safety Net (VSN) is a global network of websites, established by the World Health Organization, that provides reliable information on vaccine safety.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Vaccine Safety Net (VSN) globalna je mreža portala koju je uspostavila Svjetska zdravstvena organizacija i koja nudi pouzdane informacije o sigurnosti cjepiva.</seg>
</tuv>
</tu>
<tu tuid="155">
<prop type="lengthRatio">0.8514851485148515</prop>
<tuv xml:lang="en">
<seg>Below are links to official websites with information on vaccination from public health organisations of the European Union (EU) and European Economic Area (EEA) countries.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>U nastavku su poveznice na službena mrežna mjesta s informacijama o cijepljenju koje su izradile organizacije javnog zdravstva država članica Europske unije (EU) i Europskog gospodarskog prostora (EGP).</seg>
</tuv>
</tu>
<tu tuid="156">
<prop type="lengthRatio">1.0738636363636365</prop>
<tuv xml:lang="en">
<seg>This section provides links to the websites of other health organisations both at national and international level, in order to facilitate access to trusted sources of information, such as:</seg>
</tuv>
<tuv xml:lang="hr">
<seg>U ovoj rubrici pronaći ćete poveznice na mrežna mjesta drugih nacionalnih i međunarodnih zdravstvenih organizacija, koje će vam olakšati pristup pouzdanim izvorima informacija.</seg>
</tuv>
</tu>
<tu tuid="157">
<prop type="lengthRatio">0.35023041474654376</prop>
<tuv xml:lang="en">
<seg>For more information about the network visit: https://vaccinesafetynet.org .</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Ako želite više informacija o toj mreži, posjetite: https://vaccinesafetynet.org . Informacije o članicama mreže VSN i poveznice na njihova mrežna mjesta dostupne su ovdje: https://www.vaccinesafetynet.org/vsn/network</seg>
</tuv>
</tu>
<tu tuid="158">
<prop type="lengthRatio">1.096</prop>
<tuv xml:lang="en">
<seg>With all the information that is available on the internet and circulating on social media on vaccination, people may sometimes get lost.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Ljudi se ponekad mogu izgubiti u mnoštvu informacija o cijepljenju koje su dostupne na internetu i kolaju društvenim mrežama.</seg>
</tuv>
</tu>
<tu tuid="159">
<prop type="lengthRatio">1.2105263157894737</prop>
<tuv xml:lang="en">
<seg>Thousands of volunteers</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Tisuće dobrovoljaca</seg>
</tuv>
</tu>
<tu tuid="160">
<prop type="lengthRatio">0.8831168831168831</prop>
<tuv xml:lang="en">
<seg>its ingredients, including its inactive ingredients or ‘excipients';</seg>
</tuv>
<tuv xml:lang="hr">
<seg>njegovi sastojci, uključujući njegove neaktivne sastojke ili „pomoćne tvari";</seg>
</tuv>
</tu>
<tu tuid="161">
<prop type="lengthRatio">0.7794117647058824</prop>
<tuv xml:lang="en">
<seg>This involves tests in the laboratory and in animals.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Pod tim se podrazumijeva testiranje u laboratoriju i na životinjama.</seg>
</tuv>
</tu>
<tu tuid="162">
<prop type="lengthRatio">0.6875</prop>
<tuv xml:lang="en">
<seg>its purity;</seg>
</tuv>
<tuv xml:lang="hr">
<seg>njegova čistoća;</seg>
</tuv>
</tu>
<tu tuid="163">
<prop type="lengthRatio">1.0869565217391304</prop>
<tuv xml:lang="en">
<seg>What is the optimal dose?</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Koja je optimalna doza?</seg>
</tuv>
</tu>
<tu tuid="164">
<prop type="lengthRatio">0.9090909090909091</prop>
<tuv xml:lang="en">
<seg>Is the vaccine safe?</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Je li cjepivo sigurno?</seg>
</tuv>
</tu>
<tu tuid="165">
<prop type="lengthRatio">0.8421052631578947</prop>
<tuv xml:lang="en">
<seg>This programme has to follow the procedures and protocols set by the regulators:</seg>
</tuv>
<tuv xml:lang="hr">
<seg>U sklopu programa moraju se slijediti postupci i protokoli koje je utvrdilo regulatorno tijelo:</seg>
</tuv>
</tu>
<tu tuid="166">
<prop type="lengthRatio">0.967391304347826</prop>
<tuv xml:lang="en">
<seg>These include the European Medicines Agency and other regulators in the EU/EEA countries.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Ta su tijela Europska agencija za lijekove i druga regulatorna tijela u državama EU-a/EGP-a.</seg>
</tuv>
</tu>
<tu tuid="167">
<prop type="lengthRatio">1.2777777777777777</prop>
<tuv xml:lang="en">
<seg>how it is manufactured.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>način proizvodnje.</seg>
</tuv>
</tu>
<tu tuid="168">
<prop type="lengthRatio">0.8888888888888888</prop>
<tuv xml:lang="en">
<seg>Testing includes checking the vaccine's quality:</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Ispitivanjem je obuhvaćena provjera kvalitete cjepiva:</seg>
</tuv>
</tu>
<tu tuid="169">
<prop type="lengthRatio">1.46</prop>
<tuv xml:lang="en">
<seg>How are the immune systems of the participants responding to the vaccine?</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Kako imunosni sustav sudionika reagira na cjepivo?</seg>
</tuv>
</tu>
<tu tuid="170">
<prop type="lengthRatio">0.7947019867549668</prop>
<tuv xml:lang="en">
<seg>The vaccine developer tests the vaccine in three phases of clinical trials, with larger numbers of people in each phase.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Subjekt koji razvija cjepivo provodi u sklopu testiranja tri faze kliničkog ispitivanja cjepiva pri čemu je u svakoj fazi uključen sve veći broj ljudi.</seg>
</tuv>
</tu>
<tu tuid="171">
<prop type="lengthRatio">1.225</prop>
<tuv xml:lang="en">
<seg>What are the most common short-term side effects?</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Koje su najčešće kratkotrajne nuspojave?</seg>
</tuv>
</tu>
<tu tuid="172">
<prop type="lengthRatio">1.0650887573964498</prop>
<tuv xml:lang="en">
<seg>At the end of the testing programme, the vaccine developer submits the results to the medicines regulatory authorities in Europe as part of a ‘marketing authorisation' application.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Nakon programa testiranja subjekt koji razvija cjepivo podnosi rezultate regulatornom tijelu za lijekove u Europi kao dio zahtjeva za „odobrenje za stavljanje u promet".</seg>
</tuv>
</tu>
<tu tuid="173">
<prop type="lengthRatio">0.8783068783068783</prop>
<tuv xml:lang="en">
<seg>This is followed by a clinical testing programme in humans, which can take around ten years from initial concept to authorisation and must adhere to strict standards.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Potom slijedi klinički program testiranja na ljudima, koji može trajati oko 10 godina i započinje s inicijalnim konceptom, a završava s odobrenjem, te mora biti u skladu sa strogim normama.</seg>
</tuv>
</tu>
<tu tuid="174">
<prop type="lengthRatio">0.765</prop>
<tuv xml:lang="en">
<seg>Before a vaccine can be approved in the EU, it has to undergo rigorous testing by its developer and then scientific evaluation by regulatory authorities.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Prije nego što se cjepivo može odobriti u EU-u, ono mora biti podvrgnuto strogom ispitivanju od strane subjekta koji razvija cjepivo, a nakon toga znanstvenoj procjeni koju provode regulatorna tijela.</seg>
</tuv>
</tu>
<tu tuid="175">
<prop type="lengthRatio">1.0</prop>
<tuv xml:lang="en">
<seg>The companies are required to conduct stringent testing, for which the acceptance criteria are pre-defined by the authorities, on each batch of vaccine released onto the EU market.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Od tvrtki se zahtijeva da provedu stroga ispitivanja čije su kriterije prihvatljivosti unaprijed definirala nadležna tijela, za svaku seriju cjepiva stavljenu u promet unutar EU-a.</seg>
</tuv>
</tu>
<tu tuid="176">
<prop type="lengthRatio">0.8870967741935484</prop>
<tuv xml:lang="en">
<seg>Then the vaccine developer tests the vaccine's effects.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Nakon toga subjekt koji razvija cjepivo testira njegov učinak.</seg>
</tuv>
</tu>
<tu tuid="177">
<prop type="lengthRatio">1.0909090909090908</prop>
<tuv xml:lang="en">
<seg>They can also run tests to make sure that the batches of vaccines released onto the market are of the expected quality and have been manufactured correctly.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Mogu provoditi i ispitivanja kako bi bila sigurna da su serije cjepiva stavljene u promet odgovarajuće kvalitete te da su ispravno proizvedene.</seg>
</tuv>
</tu>
<tu tuid="178">
<prop type="lengthRatio">0.952054794520548</prop>
<tuv xml:lang="en">
<seg>Medicines regulatory authorities can carry out inspections to make sure that the information the vaccine developer provides is trustworthy.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Regulatorna tijela za lijekove provode provjere kako bi osigurala da su informacije o cjepivu koje je naveo subjekt koji razvija cjepivo pouzdane.</seg>
</tuv>
</tu>
<tu tuid="179">
<prop type="lengthRatio">1.0</prop>
<tuv xml:lang="en">
<seg>The regulators can only approve the vaccine if its scientific evaluation of the tests results show that the vaccine's benefits are greater than its risks .</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Regulatorna tijela mogu tek onda odobriti cjepivo ako je znanstvenom procjenom rezultata ispitivanja utvrđeno da koristi cjepiva nadmašuju njegove rizike .</seg>
</tuv>
</tu>
<tu tuid="180">
<prop type="lengthRatio">1.4074074074074074</prop>
<tuv xml:lang="en">
<seg>What are the most common side effects?</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Koje su najčešće nuspojave?</seg>
</tuv>
</tu>
<tu tuid="181">
<prop type="lengthRatio">1.4761904761904763</prop>
<tuv xml:lang="en">
<seg>Are there serious side effects?</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Djelotvornost cjepiva</seg>
</tuv>
</tu>
<tu tuid="182">
<prop type="lengthRatio">0.543859649122807</prop>
<tuv xml:lang="en">
<seg>Twitter Facebook Linked In Mail</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Praćenje sigurnosti cjepiva i izvješćivanje o nuspojavama</seg>
</tuv>
</tu>
<tu tuid="183">
<prop type="lengthRatio">1.0204081632653061</prop>
<tuv xml:lang="en">
<seg>European Centre for Disease Prevention and Control</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Europski centar za sprečavanje i kontrolu bolesti</seg>
</tuv>
</tu>
<tu tuid="184">
<prop type="lengthRatio">0.8620689655172413</prop>
<tuv xml:lang="en">
<seg>European Medicines Agency</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Europska agencija za lijekove</seg>
</tuv>
</tu>
<tu tuid="185">
<prop type="lengthRatio">1.3865546218487395</prop>
<tuv xml:lang="en">
<seg>It is alone responsible for drawing up proposals for new European legislation, and it implements the decisions of the European Parliament and the Council of the EU .</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Jedina je nadležna za pripremu prijedloga novog zakonodavstva EU-a te provodi odluke Europskog parlamenta i Vijeća EU-a</seg>
</tuv>
</tu>
<tu tuid="186">
<prop type="lengthRatio">0.8767123287671232</prop>
<tuv xml:lang="en">
<seg>These experts carry out the work of EMA's scientific committees.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Ti stručnjaci obavljaju djelatnosti u sklopu EMA-inih znanstvenih odbora.</seg>
</tuv>
</tu>
<tu tuid="187">
<prop type="lengthRatio">1.2542372881355932</prop>
<tuv xml:lang="en">
<seg>The European Commission is the EU's politically independent executive arm.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Europska komisija politički je neovisna izvršna grana EU-a.</seg>
</tuv>
</tu>
<tu tuid="188">
<prop type="lengthRatio">0.9514563106796117</prop>
<tuv xml:lang="en">
<seg>EMA is a networking organisation whose activities involve thousands of experts from across Europe.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>EMA je organizacija čije aktivnosti obuhvaćaju mrežu od više tisuća stručnjaka iz svih dijelova Europe.</seg>
</tuv>
</tu>
<tu tuid="189">
<prop type="lengthRatio">1.064516129032258</prop>
<tuv xml:lang="en">
<seg>(1) The European Commission, ECDC and EMA have mechanisms in place in order to ensure impartiality.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>(1) Europska komisija, ECDC i EMA imaju uspostavljene mehanizme za osiguranje nepristranosti.</seg>
</tuv>
</tu>
<tu tuid="190">
<prop type="lengthRatio">0.8469387755102041</prop>
<tuv xml:lang="en">
<seg>The Commission is divided into departments that develop policies in specific areas.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>. Komisija je organizirana na temelju glavnih uprava koje razvijaju politiku za određena područja.</seg>
</tuv>
</tu>
<tu tuid="191">
<prop type="lengthRatio">0.898876404494382</prop>
<tuv xml:lang="en">
<seg>EMA and its scientific committees examine all available data and assess their benefits and risks before they are approved and while they are marketed in the EU.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>EMA i njeni znanstveni odbori analiziraju sve dostupne podatke te procjenjuju njihove koristi i rizike prije izdavanja odobrenja kao i tijekom njihova stavljanja na tržište EU-a.</seg>
</tuv>
</tu>
<tu tuid="192">
<prop type="lengthRatio">1.0</prop>
<tuv xml:lang="en">
<seg>This is to ensure that staff and experts do not, in the performance of their duties, deal with matters in which they may, directly or indirectly, have a personal interest that could impair their independence.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Time se osigurava da osoblje i stručnjaci tijekom izvršavanja svojih dužnosti ne rade na predmetima u kojima bi, izravno ili neizravno, mogli imati osobni interes koji bi mogao ugroziti njihovu nepristranost.</seg>
</tuv>
</tu>
<tu tuid="193">
<prop type="lengthRatio">0.9053254437869822</prop>
<tuv xml:lang="en">
<seg>Staff and experts are required to declare any personal interest or any interest in any business or organisation that could compromise their impartiality.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Osoblje i stručnjaci dužni su prijaviti bilo kakav osobni interes ili interes u bilo kakvom poslovanju odnosno organizaciji koji bi mogao ugroziti njihovu nepristranost.</seg>
</tuv>
</tu>
<tu tuid="194">
<prop type="lengthRatio">0.9043478260869565</prop>
<tuv xml:lang="en">
<seg>Communication and scientific experts in these organisations are involved in developing the contents (1).</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Znanstveni stručnjaci, kao i oni za komunikaciju, u spomenutim organizacijama uključeni su u pripremu sadržaja (1).</seg>
</tuv>
</tu>
<tu tuid="195">
<prop type="lengthRatio">0.9661016949152542</prop>
<tuv xml:lang="en">
<seg>EMA ensures the efficacy, quality and safety of vaccines.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>EMA osigurava djelotvornost, kvalitetu i sigurnost cjepiva.</seg>
</tuv>
</tu>
<tu tuid="196">
<prop type="lengthRatio">1.1337579617834395</prop>
<tuv xml:lang="en">
<seg>It also provides an overview of the mechanisms in place in the European Union (EU) to ensure that available vaccines conform to the highest standards of safety and effectiveness.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Također sadrži pregled mehanizama u Europskoj uniji (EU) kojima se osigurava usklađenost dostupnih cjepiva s najvišim standardima sigurnosti i učinkovitosti.</seg>
</tuv>
</tu>
<tu tuid="197">
<prop type="lengthRatio">0.9318181818181818</prop>
<tuv xml:lang="en">
<seg>EMA works closely with European and international partners and shares information on vaccines and good regulatory practice.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>EMA blisko surađuje s europskim i međunarodnim partnerima te razmjenjuje informacije o cjepivima kao i pozitivnu regulatornu praksu.</seg>
</tuv>
</tu>
<tu tuid="198">
<prop type="lengthRatio">0.9115646258503401</prop>
<tuv xml:lang="en">
<seg>ECDC also maintains the Vaccine Scheduler , an online, interactive platform showing the vaccination schedules of all EU Member States.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>ECDC također održava raspored cijepljenja , interaktivnu internetsku platformu koja prikazuje rasporede cijepljenja u svim državama članicama EU-a.</seg>
</tuv>
</tu>
<tu tuid="199">
<prop type="lengthRatio">1.048951048951049</prop>
<tuv xml:lang="en">
<seg>Representatives from EU and EEA countries' public health organisations were consulted for finalising the website's contents and its language versions.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Predstavnici javnog zdravstva iz država EU-a i EGP-a konzultirani su u završnoj fazi pripreme sadržaja za mrežno mjesto i oko jezičnih verzija.</seg>
</tuv>
</tu>
<tu tuid="200">
<prop type="lengthRatio">1.10989010989011</prop>
<tuv xml:lang="en">
<seg>ECDC is an EU scientific agency aimed at strengthening Europe's defences against infectious diseases.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>ECDC je znanstvena agencija EU-a čiji je cilj jačati obranu protiv zaraznih bolesti u EU-u.</seg>
</tuv>
</tu>
<tu tuid="201">
<prop type="lengthRatio">0.9532374100719424</prop>
<tuv xml:lang="en">
<seg>The core functions cover a wide spectrum of activities: surveillance, epidemic intelligence, response, scientific advice, microbiology, preparedness, public health training, international relations, health communication, and the scientific journal Eurosurveillance.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Osnovna djelatnost agencije obuhvaća razne aktivnosti: nadzor, epidemiološku inteligenciju, odgovore, znanstvene savjete, mikrobiologiju, pripravnost, obuku u području javnog zdravstva, međunarodne odnose, komunikaciju u području zdravstva i znanstveni časopis Eurosurveillance.</seg>
</tuv>
</tu>
<tu tuid="202">
<prop type="lengthRatio">1.0382978723404255</prop>
<tuv xml:lang="en">
<seg>This website was developed by the European Centre for Disease Prevention and Control (ECDC), in partnership with the European Commission, specifically, its Department on Health and Food Safety (DG SANTE) and the European Medicines Agency (EMA).</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Mrežno mjesto razvio je Europski centar za sprečavanje i kontrolu bolesti (ECDC) u partnerstvu s Europskom komisijom, točnije s njenom Glavnom upravom za zdravlje i sigurnost hrane (DG SANTE) te s Europskom agencijom za lijekove (EMA).</seg>
</tuv>
</tu>
<tu tuid="203">
<prop type="lengthRatio">1.2211538461538463</prop>
<tuv xml:lang="en">
<seg>The main purpose of this website is to provide accurate, objective, up-to-date evidence on vaccines and vaccination in general.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Osnovna je svrha ovog mrežnog mjesta pružiti točne, objektivne i ažurne podatke o cjepivu i cijepljenju.</seg>
</tuv>
</tu>
<tu tuid="204">
<prop type="lengthRatio">1.1595092024539877</prop>
<tuv xml:lang="en">
<seg>The European Medicines Agency (EMA) is a decentralized agency of the European Union (EU) responsible for the scientific evaluation, supervision and safety monitoring of medicines in the EU.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Europska agencija za lijekove (EMA) decentralizirana je agencija Europske unije (EU) nadležna za znanstvenu procjenu, nadzor i praćenje sigurnosti lijekova u EU-u.</seg>
</tuv>
</tu>
<tu tuid="205">
<prop type="lengthRatio">0.9820359281437125</prop>
<tuv xml:lang="en">
<seg>One of the departments is DG for Health and Food Safety , responsible for EU policy on food safety and health and for monitoring the implementation of related laws.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Jedna od njih je i Glavna uprava za zdravlje i sigurnost hrane , nadležna za politiku EU-a u području sigurnosti hrane te za praćenje provedbe povezanog zakonodavstva.</seg>
</tuv>
</tu>
<tu tuid="206">
<prop type="lengthRatio">0.8985507246376812</prop>
<tuv xml:lang="en">
<seg>In the area of vaccine-preventable diseases, ECDC provides regular surveillance data, e.g. the number of confirmed cases, and scientific advice on vaccines, monitors disease outbreaks and develops materials to support communication on immunisation.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>U području bolesti koje se mogu spriječiti cijepljenjem, ECDC redovno osigurava podatke proistekle iz nadzora, kao što je broj potvrđenih slučajeva te znanstvene savjete o cjepivima, prati izbijanja epidemija i razvija materijale kojima se podržava komunikacija o cijepljenju.</seg>
</tuv>
</tu>
<tu tuid="207">
<prop type="lengthRatio">0.7647058823529411</prop>
<tuv xml:lang="en">
<seg>Read more: https://ec.europa.eu/health/vaccination/overview_en and https://ec.europa.eu/info/departments/health-and-food-safety_en</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Više informacija nalazi se na sljedećim poveznicama: https://ec.europa.eu/health/vaccination/overview_en i https://ec.europa.eu/info/departments/health-and-food-safety_hr</seg>
</tuv>
</tu>
<tu tuid="208">
<prop type="lengthRatio">0.8088235294117647</prop>
<tuv xml:lang="en">
<seg>For more information visit: https://www.ema.europa.eu /</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Više informacija nalazi se na poveznici: https://www.ema.europa.eu /</seg>
</tuv>
</tu>
<tu tuid="209">
<prop type="lengthRatio">0.8088235294117647</prop>
<tuv xml:lang="en">
<seg>For more information visit: https://www.ecdc.europa.eu/</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Više informacija nalazi se na poveznici: https://www.ecdc.europa.eu/</seg>
</tuv>
</tu>
<tu tuid="210">
<prop type="lengthRatio">0.84375</prop>
<tuv xml:lang="en">
<seg>The initiative aims to tackle vaccine hesitancy, improve coordination on vaccine procurement, support research and innovation, and strengthen EU cooperation on vaccine-preventable diseases.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>. Cilj je inicijative odgovoriti na oklijevanje s cijepljenjem, poboljšati koordinaciju u nabavi cjepiva, podržati istraživanje i razvoj te ojačati suradnju unutar EU-a u pogledu bolesti koje se mogu spriječiti cijepljenjem.</seg>
</tuv>
</tu>
<tu tuid="211">
<prop type="lengthRatio">1.0872093023255813</prop>
<tuv xml:lang="en">
<seg>It is an initiative of the European Union and was developed following the Council Recommendation on Strengthened Cooperation against Vaccine Preventable Diseases adopted in December 2018.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Ova je inicijativa Europske unije pokrenuta na temelju Preporuke Vijeća o jačoj suradnji u suzbijanju bolesti koje se mogu spriječiti cijepljenjem usvojene u prosincu 2018.</seg>
</tuv>
</tu>
<tu tuid="212">
<prop type="lengthRatio">0.8823529411764706</prop>
<tuv xml:lang="en">
<seg>To improve vaccination uptake, the Council adopted a Recommendation to strengthen the EU cooperation on vaccine-preventable diseases in December 2018.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>S ciljem postizanja veće procijepljenosti, Vijeće je u prosincu 2018. usvojilo Preporuke o jačoj suradnji u EU-u u suzbijanju bolesti koje se mogu spriječiti cijepljenjem</seg>
</tuv>
</tu>
<tu tuid="213">
<prop type="lengthRatio">0.47058823529411764</prop>
<tuv xml:lang="en">
<seg>About us</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Europska komisija</seg>
</tuv>
</tu>
<tu tuid="214">
<prop type="lengthRatio">1.0379746835443038</prop>
<tuv xml:lang="en">
<seg>It is also spread via secretions on hands, tissues and surfaces that people touch.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Također se širi putem sekreta preko ruku, tkiva i površina koje ljudi dodiruju.</seg>
</tuv>
</tu>
<tu tuid="215">
<prop type="lengthRatio">0.945054945054945</prop>
<tuv xml:lang="en">
<seg>Patients are advised to seek medical advice if their condition continues to get worse.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Bolesnicima se savjetuje da potraže liječnički savjet ako im se stanje nastavi pogoršavati.</seg>
</tuv>
</tu>
<tu tuid="216">
<prop type="lengthRatio">1.35</prop>
<tuv xml:lang="en">
<seg>Children are infected slightly more often than adults.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Djeca se zaraze nešto češće od odraslih.</seg>
</tuv>
</tu>
<tu tuid="217">
<prop type="lengthRatio">0.8352941176470589</prop>
<tuv xml:lang="en">
<seg>The 2009 A(H1N1)pdm09 influenza pandemic accounted for 123 000 to 203 000 deaths worldwide and a significant global socio-economic burden (3).</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Pandemija gripe 2009 A(H1N1)pdm09 za posljedicu je imala između 123 000 do 203 000 smrtnih slučajeva širom svijeta i predstavljala značajan društveno-ekonomski teret (3).</seg>
</tuv>
</tu>
<tu tuid="218">
<prop type="lengthRatio">0.9157894736842105</prop>
<tuv xml:lang="en">
<seg>The World Health Organization (WHO) also recommends vaccination for healthcare workers.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Svjetska zdravstvena organizacija (SZO) također preporuča cijepljenje i zdravstvenim radnicima.</seg>
</tuv>
</tu>
<tu tuid="219">
<prop type="lengthRatio">1.1319444444444444</prop>
<tuv xml:lang="en">
<seg>Most EU Member States follow the WHO recommendations to vaccinate pregnant women, and some follow recommendations to vaccinate healthy children aged 6 - 59 months.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Većina država članica EU-a prati preporuke SZO-a o cijepljenju trudnica, a neke i preporuke o cijepljenju zdrave djece u dobi od 6 - 59 mjeseci.</seg>
</tuv>
</tu>
<tu tuid="220">
<prop type="lengthRatio">0.9121621621621622</prop>
<tuv xml:lang="en">
<seg>Even so, about half of the children and working-age adults needing admission to intensive care have no pre-existing medical conditions.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Bez obzira na to, gotovo polovica djece i radno sposobnih odraslih osoba čije stanje zahtijeva intenzivnu njegu nemaju drugih zdravstvenih problema.</seg>
</tuv>
</tu>
<tu tuid="221">
<prop type="lengthRatio">1.0307692307692307</prop>
<tuv xml:lang="en">
<seg>Antiviral medicines, taken as rapidly as possible after illness onset, are safe and effective measures for the treatment of influenza.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Protuvirusni lijekovi koji se uzimaju što je prije moguće nakon nastupa bolesti sigurne su i djelotvorne mjere za liječenje gripe.</seg>
</tuv>
</tu>
<tu tuid="222">
<prop type="lengthRatio">0.8571428571428571</prop>
<tuv xml:lang="en">
<seg>sore throat;</seg>
</tuv>
<tuv xml:lang="hr">
<seg>upaljeno grlo;</seg>
</tuv>
</tu>
<tu tuid="223">
<prop type="lengthRatio">1.316326530612245</prop>
<tuv xml:lang="en">
<seg>Approximately 20% of the population gets infected with influenza each year and one in four infected people will develop symptoms.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Gripom se svake godine zarazi otprilike 20 % stanovništva, a svaka četvrta osoba razvije simptome.</seg>
</tuv>
</tu>
<tu tuid="224">
<prop type="lengthRatio">1.164021164021164</prop>
<tuv xml:lang="en">
<seg>The mortality rate due to influenza has been estimated in the EU/EEA countries participating to the EuroMOMO network (1) to be as high as 25 deaths per 100 000 population in the 2016/27 and 2017/18 influenza seasons (2).</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Stopa smrtnosti zbog gripe procijenjena je u državama EU-a/EGP-a koje sudjeluju u mreži EuroMOMO (1) na 25 smrtnih slučajeva na 100 000 osoba u sezonama gripe 2016./2017. i 2017./2018. (2).</seg>
</tuv>
</tu>
<tu tuid="225">
<prop type="lengthRatio">1.0350877192982457</prop>
<tuv xml:lang="en">
<seg>Vaccination is the most effective way to prevent influenza.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Cijepljenje je najučinkovitiji način za suzbijanje gripe.</seg>
</tuv>
</tu>
<tu tuid="226">
<prop type="lengthRatio">1.0833333333333333</prop>
<tuv xml:lang="en">
<seg>The EU Member States recommend seasonal influenza vaccination for risk groups, such as the elderly, as well as individuals with chronic medical conditions like heart disease, problems with the lungs and airways, diabetes or immune system problems.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Države članice EU-a preporučuju sezonsko cjepivo protiv gripe za rizične skupine poput starijih osoba i osoba s kroničnim bolestima, kao što su bolesti srca, problemi s plućima i dišnim putevima, dijabetes ili imunosni problemi.</seg>
</tuv>
</tu>
<tu tuid="227">
<prop type="lengthRatio">1.0</prop>
<tuv xml:lang="en">
<seg>In some cases patients develop bacterial complications following influenza infection and need to be treated with antibiotics.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>U nekim slučajevima bolesnici razviju bakterijske komplikacije nakon zaraze gripom te im je potrebno liječenje antibioticima.</seg>
</tuv>
</tu>
<tu tuid="228">
<prop type="lengthRatio">0.8714285714285714</prop>
<tuv xml:lang="en">
<seg>Severe illness and complications are more common in very young infants, the frail elderly and certain medical risk groups.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Ozbiljan oblik bolesti i komplikacije češći su kod novorođenčadi, krhkih starijih osoba i određenih skupina izloženih zdravstvenim rizicima.</seg>
</tuv>
</tu>
<tu tuid="229">
<prop type="lengthRatio">1.2571428571428571</prop>
<tuv xml:lang="en">
<seg>Animals can also be infected with influenza.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>I životinje mogu oboljeti od gripe.</seg>
</tuv>
</tu>
<tu tuid="230">
<prop type="lengthRatio">1.2372881355932204</prop>
<tuv xml:lang="en">
<seg>A pandemic is the rapid spread of a new human influenza around the world.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Pandemija je brzo širenje novog virusa gripe širom svijeta.</seg>
</tuv>
</tu>
<tu tuid="231">
<prop type="lengthRatio">1.0394088669950738</prop>
<tuv xml:lang="en">
<seg>In addition to vaccination, antiviral medicines have been shown to be safe and effective measures to prevent influenza infection or to reduce the severity of infection in certain settings, such as nursing homes.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Uz cijepljenje, protuvirusni lijekovi pokazali su se sigurnim i djelotvornim mjerama za suzbijanje infekcije gripom ili u smanjenju težine infekcije na određenim mjestima kao što su domovi umirovljenika.</seg>
</tuv>
</tu>
<tu tuid="232">
<prop type="lengthRatio">0.9457364341085271</prop>
<tuv xml:lang="en">
<seg>People with pre-existing medical conditions are at higher risk of their condition worsening following influenza infection.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Osobe s postojećim zdravstvenim problemima izložene su većem riziku od pogoršanja zdravstvenog stanja nakon što se zaraze gripom.</seg>
</tuv>
</tu>
<tu tuid="233">
<prop type="lengthRatio">1.125</prop>
<tuv xml:lang="en">
<seg>Complications of influenza include pneumonia and encephalitis (inflammation of the brain).</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Komplikacije gripe uključuju upalu pluća i encefalitis (upalu moždanih stanica).</seg>
</tuv>
</tu>
<tu tuid="234">
<prop type="lengthRatio">1.0568181818181819</prop>
<tuv xml:lang="en">
<seg>Influenza pandemics happen when a new strain of a flu virus appears which can infect humans, to which most people have no immunity and which can transmit efficiently from human to human.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Do pandemije gripe dolazi kad se pojavi novi soj virusa gripe koji je zarazan za ljude, protiv kojeg većina ljudi nije razvila imunitet i koji se lako prenosi s osobe na osobu.</seg>
</tuv>
</tu>
<tu tuid="235">
<prop type="lengthRatio">1.1071428571428572</prop>
<tuv xml:lang="en">
<seg>The severity of the disease varies widely, from no symptoms at all through to severe illness.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Težina bolesti značajno varira, od izostanka simptoma do vrlo teškog oblika bolesti.</seg>
</tuv>
</tu>
<tu tuid="236">
<prop type="lengthRatio">0.9504950495049505</prop>
<tuv xml:lang="en">
<seg>In some cases, humans can be infected by animals, such as in cases of avian and swine influenza.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>U nekim se slučajevima ljudi zaraze od životinja, kao što je bio slučaj s ptičjom i svinjskom gripom.</seg>
</tuv>
</tu>
<tu tuid="237">
<prop type="lengthRatio">0.8817204301075269</prop>
<tuv xml:lang="en">
<seg>In uncomplicated cases, symptoms resolve spontaneously within one week from onset.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>U slučajevima bez komplikacija simptomi se sami povuku unutar tjedan dana od nastupa bolesti.</seg>
</tuv>
</tu>
<tu tuid="238">
<prop type="lengthRatio">1.0518518518518518</prop>
<tuv xml:lang="en">
<seg>The EU Council Recommendation on seasonal influenza vaccination encourages countries to improve vaccination coverage among healthcare workers.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Preporuka Europskog Vijeća o cijepljenju protiv sezonske gripe potiče zemlje na povećanje procijepljenosti među zdravstvenim radnicima.</seg>
</tuv>
</tu>
<tu tuid="239">
<prop type="lengthRatio">0.7818181818181819</prop>
<tuv xml:lang="en">
<seg>For those that do, common symptoms include:</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Osobe koje se razbole obično razviju sljedeće simptome:</seg>
</tuv>
</tu>
<tu tuid="240">
<prop type="lengthRatio">0.9032258064516129</prop>
<tuv xml:lang="en">
<seg>Who is at risk of influenza?</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Tko je izložen riziku od gripe?</seg>
</tuv>
</tu>
<tu tuid="241">
<prop type="lengthRatio">1.3877551020408163</prop>
<tuv xml:lang="en">
<seg>Not everyone who is infected with an influenza virus becomes unwell.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Ne razboli se svaka osoba zaražena virusom gripe.</seg>
</tuv>
</tu>
<tu tuid="242">
<prop type="lengthRatio">0.9901960784313726</prop>
<tuv xml:lang="en">
<seg>An update of seasonal influenza vaccines is needed yearly, since influenza viruses constantly evolve.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Cjepivo protiv sezonske gripe svake je godine potrebno izmijeniti jer virus gripe kontinuirano mutira.</seg>
</tuv>
</tu>
<tu tuid="243">
<prop type="lengthRatio">0.7288135593220338</prop>
<tuv xml:lang="en">
<seg>However, antivirals are generally recommended for severe or rapidly progressing cases.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Međutim, protuvirusni se lijekovi u pravilu preporučuju za teške oblike bolesti i one koji se izuzetno brzo razvijaju.</seg>
</tuv>
</tu>
<tu tuid="244">
<prop type="lengthRatio">1.263157894736842</prop>
<tuv xml:lang="en">
<seg>How is influenza spread?</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Kako se gripa širi?</seg>
</tuv>
</tu>
<tu tuid="245">
<prop type="lengthRatio">1.1195652173913044</prop>
<tuv xml:lang="en">
<seg>In addition to seasonal epidemics, novel influenza viruses may occasionally emerge and cause pandemics.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Uz sezonske epidemije gripe, povremeno se razviju novi virusi gripe koji uzrokuju pandemiju.</seg>
</tuv>
</tu>
<tu tuid="246">
<prop type="lengthRatio">1.0333333333333334</prop>
<tuv xml:lang="en">
<seg>How can influenza be prevented?</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Kako se gripa može spriječiti?</seg>
</tuv>
</tu>
<tu tuid="247">
<prop type="lengthRatio">1.4814814814814814</prop>
<tuv xml:lang="en">
<seg>What are the complications of influenza?</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Koje su komplikacije gripe?</seg>
</tuv>
</tu>
<tu tuid="248">
<prop type="lengthRatio">1.3846153846153846</prop>
<tuv xml:lang="en">
<seg>What is influenza?</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Što je gripa?</seg>
</tuv>
</tu>
<tu tuid="249">
<prop type="lengthRatio">1.6153846153846154</prop>
<tuv xml:lang="en">
<seg>For most cases of influenza, patients are advised to take bed rest and drink plenty of fluids in order to manage their symptoms; staying at home also minimises the risk of infecting others.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Kod većine slučajeva gripe bolesnicima se savjetuje ležanje i uzimanje velike količine tekućine za kontrolu simptoma.</seg>
</tuv>
</tu>
<tu tuid="250">
<prop type="lengthRatio">0.8554216867469879</prop>
<tuv xml:lang="en">
<seg>This is mainly via direct contact with secretions from infectious patients, such as droplets of fluid released when they cough or breathe out.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Gripa se lako širi s osobe na osobu uglavnom putem izravnog kontakta sa sekretom zaraženog bolesnika, kao što su kapljice tekućine koje bolesnik iskašlje ili izdahne.</seg>
</tuv>
</tu>
<tu tuid="251">
<prop type="lengthRatio">1.5217391304347827</prop>
<tuv xml:lang="en">
<seg>What are the symptoms of influenza?</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Koji su simptomi gripe?</seg>
</tuv>
</tu>
<tu tuid="252">
<prop type="lengthRatio">1.1904761904761905</prop>
<tuv xml:lang="en">
<seg>How is influenza treated?</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Kako se gripa liječi?</seg>
</tuv>
</tu>
<tu tuid="253">
<prop type="lengthRatio">0.6260162601626016</prop>
<tuv xml:lang="en">
<seg>In Europe, influenza occurs in regular annual epidemics in the winter season.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>U Europi se gripa javlja kao epidemija tijekom zimskih mjeseci, a epidemiju obilježava visoka stopa hospitalizacije i smrt.</seg>
</tuv>
</tu>
<tu tuid="254">
<prop type="lengthRatio">1.3636363636363635</prop>
<tuv xml:lang="en">
<seg>More factsheets</seg>
</tuv>
<tuv xml:lang="hr">
<seg>glavobolju;</seg>
</tuv>
</tu>
<tu tuid="255">
<prop type="lengthRatio">1.8780487804878048</prop>
<tuv xml:lang="en">
<seg>These epidemics are associated with high hospitalisation rates and mortality.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>vrućicu ili osjećaj povišene temperature;</seg>
</tuv>
</tu>
<tu tuid="256">
<prop type="lengthRatio">1.15</prop>
<tuv xml:lang="en">
<seg>Rubella (German measles) is a viral infection.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Rubeola (crljenac) je virusna infekcija.</seg>
</tuv>
</tu>
<tu tuid="257">
<prop type="lengthRatio">1.0</prop>
<tuv xml:lang="en">
<seg>In healthy individuals it is usually a mild disease.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>U zdravih pojedinaca rubeola je obično blaga bolest.</seg>
</tuv>
</tu>
<tu tuid="258">
<prop type="lengthRatio">0.8217821782178217</prop>
<tuv xml:lang="en">
<seg>Pertussis is a highly infectious bacterial disease involving the lungs and airways.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Ospice su vrlo zarazna virusna bolest od koje se može oboljeti u bilo kojoj dobi i koja se brzo širi.</seg>
</tuv>
</tu>
<tu tuid="259">
<prop type="lengthRatio">0.7352941176470589</prop>
<tuv xml:lang="en">
<seg>When to avoid vaccination</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Kada treba izbjegavati cijepljenje</seg>
</tuv>
</tu>
<tu tuid="260">
<prop type="lengthRatio">0.8652849740932642</prop>
<tuv xml:lang="en">
<seg>Immunocompromised patients also benefit from those around them being fully vaccinated (such as family members, caregivers), as then they are also indirectly protected.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Imunokompromitirani bolesnici također imaju koristi od toga da su osobe iz njihove okoline cijepljene (poput članova obitelji i pružatelja skrbi) jer su u tom slučaju i oni neizravno zaštićeni.</seg>
</tuv>
</tu>
<tu tuid="261">
<prop type="lengthRatio">0.837037037037037</prop>
<tuv xml:lang="en">
<seg>Anaphylaxis is a rare, rapid, extreme allergic reaction which can cause shock, swelling and difficulty breathing.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Anafilaksija je rijetka, brzo nastupajuća, ekstremno jaka alergijska reakcija koja može uzrokovati šok, oticanje i teškoće pri disanju.</seg>
</tuv>
</tu>
<tu tuid="262">
<prop type="lengthRatio">0.8646153846153846</prop>
<tuv xml:lang="en">
<seg>Certain immune system disorders (e.g. congenital immune deficiencies), or medical treatments (e.g. chemotherapy, a bone marrow or other organ transplant, or high doses of steroids) are contraindications for some vaccines, such as measles, mumps, rubella, varicella or oral typhoid.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Određeni poremećaji imunosnog sustava (poput urođenih imunosnih poremećaja), ili medicinske terapije (poput kemoterapije, presađivanja koštane srži ili organa ili visoke doze steroida) kontraindicirani su za neka cjepiva, kao što je cjepivo protiv ospica, zaušnjaka, rubeole, vodenih kozica i peroralno cjepivo protiv tifusa.</seg>
</tuv>
</tu>
<tu tuid="263">
<prop type="lengthRatio">1.1746031746031746</prop>
<tuv xml:lang="en">
<seg>It usually occurs within minutes of exposure to the source of the allergy.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Obično se razvije unutar nekoliko minuta od izlaganja alergenu.</seg>
</tuv>
</tu>
<tu tuid="264">
<prop type="lengthRatio">1.2</prop>
<tuv xml:lang="en">
<seg>In some cases, the completion of the immunisations needed is recommended prior to the start of a treatment, as during the treatment the patient may be at higher risks of infection.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>U nekim se slučajevima potrebno cijepljenje preporučuje prije početka terapije jer bolesnik tijekom terapije može biti izložen većem riziku od zaraze.</seg>
</tuv>
</tu>
<tu tuid="265">
<prop type="lengthRatio">1.0072992700729928</prop>
<tuv xml:lang="en">
<seg>Women of childbearing age should discuss with their healthcare provider which vaccines are recommended before, during and after pregnancy.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Žene reproduktivne dobi sa svojim se liječnikom trebaju posavjetovati o tome koja su cjepiva preporučena prije, tijekom i nakon trudnoće.</seg>
</tuv>
</tu>
<tu tuid="266">
<prop type="lengthRatio">1.0775193798449612</prop>
<tuv xml:lang="en">
<seg>A vaccine is contraindicated to those allergic to any of the vaccine active substances or ingredients as listed in the product information.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Cjepivo je kontraindicirano kod osoba koje su alergične na bilo koju aktivnu tvar ili sastojak naveden u informacijama o cjepivu.</seg>
</tuv>
</tu>
<tu tuid="267">
<prop type="lengthRatio">1.018348623853211</prop>
<tuv xml:lang="en">
<seg>There may be other contraindications for specific vaccines, which need discussing with the healthcare provider.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Mogu postojati i druge kontraindikacije za određena cjepiva oko kojih se potrebno posavjetovati s liječnikom.</seg>
</tuv>
</tu>
<tu tuid="268">
<prop type="lengthRatio">1.1261261261261262</prop>
<tuv xml:lang="en">
<seg>Every effort should be made to see that women receive all routinely recommended vaccines before they reach child-bearing age.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Potrebno je uložiti maksimalan napor da žene prime sva uobičajeno preporučena cjepiva prije reproduktivne dobi.</seg>
</tuv>
</tu>
<tu tuid="269">
<prop type="lengthRatio">1.0203045685279188</prop>
<tuv xml:lang="en">
<seg>Someone who experiences an anaphylactic or other serious allergic reaction following a certain vaccine should not be given that vaccine again, unless the vaccine is definitively ruled out as the cause.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Osoba koja doživi anafilaktičku reakciju ili drugu ozbiljnu alergijsku reakciju nakon određenog cjepiva ne smije više primiti to cjepivo, osim ako je ono u potpunosti isključeno kao uzrok alergije.</seg>
</tuv>
</tu>
<tu tuid="270">
<prop type="lengthRatio">0.8969072164948454</prop>
<tuv xml:lang="en">
<seg>Some vaccines are contraindicated during pregnancy, such as measles, mumps and rubella.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Neka su cjepiva kontraindicirana tijekom trudnoće, poput onih protiv ospica, zaušnjaka i rubeole.</seg>
</tuv>
</tu>
<tu tuid="271">
<prop type="lengthRatio">1.2</prop>
<tuv xml:lang="en">
<seg>A history of 'anaphylactic' or other serious allergic reaction after receiving a vaccine is a contraindication to further doses of that vaccine.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Anafilaksija ili druge ozbiljne alergijske reakcije nakon cijepljenja kontraindikacija su za dodatne doze istog cjepiva.</seg>
</tuv>
</tu>
<tu tuid="272">
<prop type="lengthRatio">2.3411764705882354</prop>
<tuv xml:lang="en">
<seg>A vaccine may be contraindicated for certain people, meaning they should not receive it. Possible contraindications should be always discussed with the healthcare provider before receiving a vaccine.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Kod nekih osoba cjepivo može biti kontraindicirano, što znači da ga ne smiju primiti.</seg>
</tuv>
</tu>
<tu tuid="273">
<prop type="lengthRatio">2.3333333333333335</prop>
<tuv xml:lang="en">
<seg>These include:</seg>
</tuv>
<tuv xml:lang="hr">
<seg>To su:</seg>
</tuv>
</tu>
<tu tuid="274">
<prop type="lengthRatio">0.8</prop>
<tuv xml:lang="en">
<seg>An example is aluminium;</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Jedan od primjera je aluminij;</seg>
</tuv>
</tu>
<tu tuid="275">
<prop type="lengthRatio">1.1846153846153846</prop>
<tuv xml:lang="en">
<seg>In addition to one or more antigens, there are other components in a vaccine.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Osim jednog ili više antigena, cjepivo sadržava i druge sastojke.</seg>
</tuv>
</tu>
<tu tuid="276">
<prop type="lengthRatio">1.1238938053097345</prop>
<tuv xml:lang="en">
<seg>adjuvants: these improve the immune response to the vaccine by making the response stronger, faster and more sustained in time.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>adjuvansi: koji poboljšavaju imunosni odgovor na cjepivo i čine ga snažnijim, bržim i održivijim tijekom vremena.</seg>
</tuv>
</tu>
<tu tuid="277">
<prop type="lengthRatio">0.9661016949152542</prop>
<tuv xml:lang="en">
<seg>These substances are consistently controlled to ensure they are present at levels that have been shown to be safe.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Te su tvari pod konstantnim nadzorom kako bi se osiguralo da su prisutne u razinama za koje se pokazalo da su sigurne.</seg>
</tuv>
</tu>
<tu tuid="278">
<prop type="lengthRatio">0.9950248756218906</prop>
<tuv xml:lang="en">
<seg>excipients: these are inactive ingredients, like water, or sodium chloride (salt), as well as the preservatives or stabilisers that help the vaccine remain unchanged during storage, keeping it active.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>pomoćne tvari: to su neaktivni sastojci, poput vode ili natrijevog klorida (soli), kao i konzervansa ili stabilizatora kojima se postiže da cjepivo tijekom skladištenja ostane nepromijenjeno i aktivno.</seg>
</tuv>
</tu>
<tu tuid="279">
<prop type="lengthRatio">0.8348623853211009</prop>
<tuv xml:lang="en">
<seg>Regulators check that their benefits are weighed against the risk of any reactions to them.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Regulatorna tijela provjeravaju omjer njihove koristi u odnosu na rizike koje reakcije na njih mogu izazvati.</seg>
</tuv>
</tu>
<tu tuid="280">
<prop type="lengthRatio">1.0136363636363637</prop>
<tuv xml:lang="en">
<seg>Whenever these substances are present at a level that might trigger a reaction in a sensitive or allergic individual, their presence is declared in the information provided to healthcare workers and patients on the vaccine.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Uvijek kada se te tvari nalaze u razinama koje mogu izazvati reakciju u osjetljivih ili alergičnih osoba njihova se prisutnost prijavi putem informacija o cjepivu koje se dostavljaju zdravstvenim radnicima i bolesnicima.</seg>
</tuv>
</tu>
<tu tuid="281">
<prop type="lengthRatio">0.9408284023668639</prop>
<tuv xml:lang="en">
<seg>There may also be trace amounts of other substances used in the manufacturing process, such as ovalbumin (a protein found in eggs) or neomycin (an antibiotic).</seg>
</tuv>
<tuv xml:lang="hr">
<seg>U tragovima mogu biti prisutne i druge tvari koje se koriste u proizvodnom postupku, poput ovalbumina (bjelančevine koja se nalazi u jajima) ili neomicina (antibiotika).</seg>
</tuv>
</tu>
<tu tuid="282">
<prop type="lengthRatio">1.0194174757281553</prop>
<tuv xml:lang="en">
<seg>For example, the package leaflet will state if there are special precautions for use of a vaccine in people with certain allergies, such as vaccines including trace amounts of egg in people with an egg allergy.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Na primjer, upute o cjepivu sadržavat će informacije o posebnim mjerama opreza pri uporabi za osobe s određenim alergijama, poput onih za cjepiva koja sadržavaju jaje u tragovima za osobe alergične na jaja.</seg>
</tuv>
</tu>
<tu tuid="283">
<prop type="lengthRatio">0.88</prop>
<tuv xml:lang="en">
<seg>Thanks to vaccination:</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Zahvaljujući cijepljenju:</seg>
</tuv>
</tu>
<tu tuid="284">
<prop type="lengthRatio">1.04</prop>
<tuv xml:lang="en">
<seg>Vaccination programmes have wider societal benefits.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Programi cijepljenja imaju šire društvene koristi.</seg>
</tuv>
</tu>
<tu tuid="285">
<prop type="lengthRatio">0.8517241379310345</prop>
<tuv xml:lang="en">
<seg>They help reduce the social, psychological and financial burdens of disease on people and governments, reducing pressures on healthcare and social care systems and enabling people to pursue productive activities including education and employment.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Oni doprinose smanjenju društvenog, psihološkog i financijskog tereta koji bolesti nameću stanovništvu i državnim institucijama, smanjuje se opterećenje sustava zdravstvene i socijalne skrbi te omogućuje ljudima da se slobodno bave produktivnim aktivnostima, kao što su obrazovanje i posao.</seg>
</tuv>
</tu>
<tu tuid="286">
<prop type="lengthRatio">1.1237113402061856</prop>
<tuv xml:lang="en">
<seg>Vaccination also prevents the development of certain types of pre-cancerous growths and cancers, for example:</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Cijepljenjem se sprječava i razvoj određenih vrsta pretkancerogenih izraslina i raka, primjerice:</seg>
</tuv>
</tu>
<tu tuid="287">
<prop type="lengthRatio">1.167883211678832</prop>
<tuv xml:lang="en">
<seg>The connected dots indicate the maximum and minimum number of previously uninfected and unvaccinated people who could get infected by a person with the disease.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Spojene točke označavaju najveći i najmanji broj prethodno nezaraženih i necijepljenih osoba koje bi se mogle zaraziti od oboljele osobe.</seg>
</tuv>
</tu>
<tu tuid="288">
<prop type="lengthRatio">0.9389312977099237</prop>
<tuv xml:lang="en">
<seg>This shows both the most conservative estimate (inner ring, darker dots) and the maximum estimate (outer ring, paler dots).</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Prikazana je i procjena najmanjeg broja (unutarnji krug, tamnije točke) i procjena najvećeg broja (vanjski krug, svijetlije točke).</seg>
</tuv>
</tu>
<tu tuid="289">
<prop type="lengthRatio">0.984375</prop>
<tuv xml:lang="en">
<seg>Vaccination helps prevent the spread of disease in communities.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Cijepljenje pomaže u sprječavanju širenja bolesti u zajednicama.</seg>
</tuv>
</tu>
<tu tuid="290">
<prop type="lengthRatio">0.927710843373494</prop>
<tuv xml:lang="en">
<seg>transmission of polio has ended in most parts of the world, including Europe.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>zaraza dječjom paralizom suzbijena je u većem dijelu svijeta, uključujući u Europi.</seg>
</tuv>
</tu>
<tu tuid="291">
<prop type="lengthRatio">1.2608695652173914</prop>
<tuv xml:lang="en">
<seg>The centre dot represent one person affected by a disease.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Središnja točka označava jednu oboljelu osobu.</seg>
</tuv>
</tu>
<tu tuid="292">
<prop type="lengthRatio">0.8041958041958042</prop>
<tuv xml:lang="en">
<seg>vaccinating against humanpapilloma virus (HPV) can help prevent cervical and other cancers caused by HPV infection;</seg>
</tuv>
<tuv xml:lang="hr">
<seg>cijepljenjem protiv humanog papilomavirusa (HPV) moguće je spriječiti rak grlića maternice i druge vrste raka koje su posljedica zaraze HPV-om;</seg>
</tuv>
</tu>
<tu tuid="293">
<prop type="lengthRatio">1.1566265060240963</prop>
<tuv xml:lang="en">
<seg>When a large percentage of a population is vaccinated, infectious diseases cannot easily spread.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Ako je procijepljen visok postotak populacije, otežano je širenje zaraznih bolesti.</seg>
</tuv>
</tu>
<tu tuid="294">
<prop type="lengthRatio">1.2</prop>
<tuv xml:lang="en">
<seg>Vaccination prevents people from getting the symptoms of the disease, which can be severe.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Cijepljenjem se sprječava izbijanje simptoma bolesti, koji mogu biti teški.</seg>
</tuv>
</tu>
<tu tuid="295">
<prop type="lengthRatio">0.9724137931034482</prop>
<tuv xml:lang="en">
<seg>Vaccination is the best way to acquire immunity against vaccine-preventable diseases, as opposed to immunity attained by getting the disease.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Cijepljenje je najbolji način stjecanja imunosti na bolesti koje se mogu spriječiti cijepljenjem, za razliku od imunosti stečene tijekom bolesti.</seg>
</tuv>
</tu>
<tu tuid="296">
<prop type="lengthRatio">1.0612244897959184</prop>
<tuv xml:lang="en">
<seg>vaccinating against hepatitis B can help prevent liver cancer caused by long-term hepatitis B infection.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>cijepljenjem protiv hepatitisa B moguće je spriječiti rak jetre uzrokovan kroničnim hepatitisom B.</seg>
</tuv>
</tu>
<tu tuid="297">
<prop type="lengthRatio">0.8043478260869565</prop>
<tuv xml:lang="en">
<seg>smallpox is now eradicated worldwide;</seg>
</tuv>
<tuv xml:lang="hr">
<seg>velike boginje iskorijenjene su širom svijeta;</seg>
</tuv>
</tu>
<tu tuid="298">
<prop type="lengthRatio">0.42696629213483145</prop>
<tuv xml:lang="en">
<seg>This is known as 'community immunity' (also referred to as 'herd immunity').</seg>
</tuv>
<tuv xml:lang="hr">
<seg>To je poznato pod nazivom „kolektivna imunost" (koja se ponekad još naziva i „imunost krda") Cijepljenjem je moguće iskorijeniti bolesti ili znatno smanjiti broj novih slučajeva.</seg>
</tuv>
</tu>
<tu tuid="299">
<prop type="lengthRatio">1.121212121212121</prop>
<tuv xml:lang="en">
<seg>When symptoms do occur, they include:</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Ako nastupe simptomi, onda su to:</seg>
</tuv>
</tu>
<tu tuid="300">
<prop type="lengthRatio">0.75</prop>
<tuv xml:lang="en">
<seg>red rash;</seg>
</tuv>
<tuv xml:lang="hr">
<seg>crveni osip;</seg>
</tuv>
</tu>
<tu tuid="301">
<prop type="lengthRatio">1.0990990990990992</prop>
<tuv xml:lang="en">
<seg>The second dose can be given one month or more after the first dose, in accordance with the national vaccination schedule.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Druga doza može se dati mjesec dana nakon prve doze ili kasnije, u skladu s nacionalnim rasporedom cijepljenja.</seg>
</tuv>
</tu>
<tu tuid="302">
<prop type="lengthRatio">1.077922077922078</prop>
<tuv xml:lang="en">
<seg>The first dose is given between 10 and 18 months of age in most European countries.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Prva se doza u većini europskih zemalja daje između 10. i 18. mjeseca života.</seg>
</tuv>
</tu>
<tu tuid="303">
<prop type="lengthRatio">1.3191489361702127</prop>
<tuv xml:lang="en">
<seg>swollen lymph glands around the ears and the back of the head;</seg>
</tuv>
<tuv xml:lang="hr">
<seg>otečeni limfni čvorovi oko ušiju i na potiljku;</seg>
</tuv>
</tu>
<tu tuid="304">
<prop type="lengthRatio">1.18</prop>
<tuv xml:lang="en">
<seg>Two doses of the vaccine are needed for maximum protection.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Za potpunu zaštitu potrebne su dvije doze cjepiva.</seg>
</tuv>
</tu>
<tu tuid="305">
<prop type="lengthRatio">1.1129032258064515</prop>
<tuv xml:lang="en">
<seg>Up to 50% of people infected with rubella do not experience symptoms.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Do 50 % osoba zaraženih virusom rubeole nema nikakve simptome.</seg>
</tuv>
</tu>
<tu tuid="306">
<prop type="lengthRatio">1.0793650793650793</prop>
<tuv xml:lang="en">
<seg>The MMR vaccine is safe and effective and has very few side effects.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Cjepivo MMR sigurno je i učinkovito te ima vrlo malo nuspojava.</seg>
</tuv>
</tu>
<tu tuid="307">
<prop type="lengthRatio">0.8947368421052632</prop>
<tuv xml:lang="en">
<seg>However, if a woman gets rubella during the first three months of pregnancy, it is very likely to result in miscarriage or a baby born with congenital anomalies known as congenital rubella syndrome (CRS).</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Međutim, ako žena tijekom prva tri mjeseca trudnoće oboli od rubeole, vrlo je vjerojatno da će doći do spontanog pobačaja ili da će novorođenče imati kongenitalnu anomaliju poznatu pod nazivom kongenitalni sindrom rubeole (CRS).</seg>
</tuv>
</tu>
<tu tuid="308">
<prop type="lengthRatio">0.9539473684210527</prop>
<tuv xml:lang="en">
<seg>Some vaccine recipients develop a non-infectious mild measles-like rash, typically 7-14 days after vaccination, which disappears within 1-3 days.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Kod nekih primatelja cjepiva razvije se neinfektivni blagi osip nalik ospicama, u pravilu 7 do14 dana nakon cijepljenja i nestaje u roku od 1 do 3 dana.</seg>
</tuv>
</tu>
<tu tuid="309">
<prop type="lengthRatio">1.0227272727272727</prop>
<tuv xml:lang="en">
<seg>Women who plan to become pregnant should check their vaccination status, as they cannot be vaccinated against rubella during pregnancy.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Žene koje planiraju trudnoću trebale bi provjeriti svoj status cijepljenja jer se tijekom trudnoće ne smiju cijepiti protiv rubeole.</seg>
</tuv>
</tu>
<tu tuid="310">
<prop type="lengthRatio">1.4375</prop>
<tuv xml:lang="en">
<seg>pain and inflammation of the joints in adults.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>bol i upala zglobova u odraslih.</seg>
</tuv>
</tu>
<tu tuid="311">
<prop type="lengthRatio">1.2474226804123711</prop>
<tuv xml:lang="en">
<seg>Anyone who has not had the disease or who has not been vaccinated with the MMR vaccine is at risk of contracting rubella.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Svatko tko nije prebolio tu bolest ili nije primio cjepivo MMR u opasnosti je od zaraze rubeolom.</seg>
</tuv>
</tu>
<tu tuid="312">
<prop type="lengthRatio">0.9381443298969072</prop>
<tuv xml:lang="en">
<seg>Mild reactions such as fever, redness or swelling at the injection site have been reported.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Prijavljene su blage nuspojave poput vrućice, crvenila ili oticanja na mjestu primjene injekcije.</seg>
</tuv>
</tu>
<tu tuid="313">
<prop type="lengthRatio">0.952</prop>
<tuv xml:lang="en">
<seg>The MMR (measles, mumps and rubella) vaccine is a combination vaccine that protects against measles, mumps and rubella.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Cjepivo MMR (protiv ospica, zaušnjaka i rubeole) kombinirano je cjepivo koje nas je nas štiti od ospica, zaušnjaka i rubeole.</seg>
</tuv>
</tu>
<tu tuid="314">
<prop type="lengthRatio">0.7878787878787878</prop>
<tuv xml:lang="en">
<seg>Who is at risk of rubella?</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Tko je izložen riziku od rubeole?</seg>
</tuv>
</tu>
<tu tuid="315">
<prop type="lengthRatio">0.90625</prop>
<tuv xml:lang="en">
<seg>How can rubella be prevented?</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Kako se rubeola može spriječiti?</seg>
</tuv>
</tu>
<tu tuid="316">
<prop type="lengthRatio">1.32</prop>
<tuv xml:lang="en">
<seg>What are the symptoms of rubella?</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Koji su simptomi rubeole?</seg>
</tuv>
</tu>
<tu tuid="317">
<prop type="lengthRatio">1.1195652173913044</prop>
<tuv xml:lang="en">
<seg>The rubella virus is spread via airborne droplets produced when the infected person coughs and sneezes.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Virus rubeole širi se zrakom u kapljicama koje nastaju kašljanjem i kihanjem zaražene osobe.</seg>
</tuv>
</tu>
<tu tuid="318">
<prop type="lengthRatio">1.0476190476190477</prop>
<tuv xml:lang="en">
<seg>How is rubella spread?</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Kako se rubeola širi?</seg>
</tuv>
</tu>
<tu tuid="319">
<prop type="lengthRatio">0.9279279279279279</prop>
<tuv xml:lang="en">
<seg>The consequences for unvaccinated pregnant women that get rubella are particularly severe, due to the likelihood that contracting the disease during pregnancy can lead to miscarriage or CRS in their babies.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Posljedice za necijepljene trudnice koje obole od rubeole posebno su ozbiljne zbog vjerojatnosti da obolijevanje tijekom trudnoće može uzrokovati spontani pobačaj ili kongenitalni sindrom rubeole kod njihove novorođenčadi.</seg>
</tuv>
</tu>
<tu tuid="320">
<prop type="lengthRatio">1.2439024390243902</prop>
<tuv xml:lang="en">
<seg>The only protection against rubella is vaccination.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Jedina zaštita od bolesti je cijepljenje.</seg>
</tuv>
</tu>
<tu tuid="321">
<prop type="lengthRatio">1.0</prop>
<tuv xml:lang="en">
<seg>How is rubella treated?</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Kako se rubeola liječi?</seg>
</tuv>
</tu>
<tu tuid="322">
<prop type="lengthRatio">0.8604651162790697</prop>
<tuv xml:lang="en">
<seg>CRS can lead to deafness, cataracts and learning disabilities in the baby.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Kongenitalni sindrom rubeole može uzrokovati gluhoću, katarktu i poteškoće pri učenju.</seg>
</tuv>
</tu>
<tu tuid="323">
<prop type="lengthRatio">0.8260869565217391</prop>
<tuv xml:lang="en">
<seg>What are the complications of rubella?</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Koje su moguće komplikacije izazvane rubeolom?</seg>
</tuv>
</tu>
<tu tuid="324">
<prop type="lengthRatio">0.9183673469387755</prop>
<tuv xml:lang="en">
<seg>For more information check the ECDC website: https://www.ecdc.europa.eu/en/pertussis/facts</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Više informacija potražite na mrežnom mjestu ECDC-a: https://www.ecdc.europa.eu/hr/pertussis/facts</seg>
</tuv>
</tu>
<tu tuid="325">
<prop type="lengthRatio">1.0761421319796953</prop>
<tuv xml:lang="en">
<seg>Note: The information contained in this factsheet is intended for the purpose of general information and should not be used as a substitute for the individual expertise and judgement of a healthcare professional.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Napomena: Informacije iznesene u ovom članku namijenjene su potrebama općeg informiranja i ne bi se smjele upotrebljavati kao zamjena za pojedinačne stručne savjete i prosudbe zdravstvenih radnika.</seg>
</tuv>
</tu>
<tu tuid="326">
<prop type="lengthRatio">0.9494949494949495</prop>
<tuv xml:lang="en">
<seg>Symptoms usually appear 7 to 10 days after infection, but may also appear up to 21 days later:</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Simptomi se obično javljaju 7 do 10 dana nakon infekcije, ali mogu se pojaviti i do 21 dan kasnije.</seg>
</tuv>
</tu>
<tu tuid="327">
<prop type="lengthRatio">1.305084745762712</prop>
<tuv xml:lang="en">
<seg>It is caused by bacteria in the mouth, nose and throat of an infected person.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Uzrokuju ga bakterije u ustima, nosu i grlu zaražene osobe.</seg>
</tuv>
</tu>
<tu tuid="328">
<prop type="lengthRatio">1.875</prop>
<tuv xml:lang="en">
<seg>More factsheets</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Hripavac</seg>
</tuv>
</tu>
<tu tuid="329">
<prop type="lengthRatio">0.9814814814814815</prop>
<tuv xml:lang="en">
<seg>Adolescents, adults, or children partially immunised generally have milder or somewhat different symptoms.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Adolescenti, odrasli i djeca koja su djelomično procijepljena obično imaju blaže ili malo drukčije simptome.</seg>
</tuv>
</tu>
<tu tuid="330">
<prop type="lengthRatio">1.1808510638297873</prop>
<tuv xml:lang="en">
<seg>They initially occur at night and then become more frequent during the day and may recur for one to two months.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Na početku se javljaju noću, a kasnije postaju sve češći danju i mogu potrajati mjesec do dva.</seg>
</tuv>
</tu>
<tu tuid="331">
<prop type="lengthRatio">0.8405797101449275</prop>
<tuv xml:lang="en">
<seg>A third or fourth dose is recommended at 11-24 months of age, and another dose between three and seven years of age.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Treću ili četvrtu dozu preporučuje se dati u dobi od 11 do 24 mjeseca, nakon čega slijedi još jedna doza u dobi između tri i sedam godina.</seg>
</tuv>
</tu>
<tu tuid="332">
<prop type="lengthRatio">0.8235294117647058</prop>
<tuv xml:lang="en">
<seg>Who is at risk of pertussis?</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Tko je izložen riziku od hripavca?</seg>
</tuv>
</tu>
<tu tuid="333">
<prop type="lengthRatio">0.994413407821229</prop>
<tuv xml:lang="en">
<seg>However, in order to be most effective, treatment must begin early in the course of disease, during the first one to two weeks before the episodes of numerous rapid coughs occur.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Međutim, kako bi bilo što učinkovitije, liječenje mora započeti u ranoj fazi bolesti, odnosno tijekom prvih tjedan do dva prije nego se jave napadi s brojnim brzim udarima kašlja.</seg>
</tuv>
</tu>
<tu tuid="334">
<prop type="lengthRatio">1.064</prop>
<tuv xml:lang="en">
<seg>Frequently, older siblings and parents who may be carrying the bacteria bring the disease home and infect an infant in the household.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Često se događa da starija braća ili roditelji koji mogu biti nositelji bakterija donesu bolest u kuću i tako zaraze dojenče.</seg>
</tuv>
</tu>
<tu tuid="335">
<prop type="lengthRatio">1.311926605504587</prop>
<tuv xml:lang="en">
<seg>Pertussis can also be spread by an individual who has only a mild form of the disease, or by an infected individual who has no symptoms at all.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Hripavac može širiti i osoba koja ima samo blag oblik bolesti ili zaražena osoba koja nema nikakvih simptoma.</seg>
</tuv>
</tu>
<tu tuid="336">
<prop type="lengthRatio">1.042857142857143</prop>
<tuv xml:lang="en">
<seg>After this phase, the coughing fits become less frequent and less severe, and the infant gradually gets better (this can take up to three months).</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Nakon te faze napadi kašlja postaju rjeđi i slabiji, a stanje dojenčeta postupno se poboljšava (za što može biti potrebno i do tri mjeseca).</seg>
</tuv>
</tu>
<tu tuid="337">
<prop type="lengthRatio">1.054421768707483</prop>
<tuv xml:lang="en">
<seg>Some countries also recommend a booster to unprotected women soon after they have delivered, to reduce the risk of transmission of the disease to the baby.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>U nekim se zemljama preporučuje i docjepljivanje nezaštićenih žena ubrzo nakon poroda kako bi se smanjio rizik od prijenosa bolesti na novorođenče.</seg>
</tuv>
</tu>
<tu tuid="338">
<prop type="lengthRatio">1.0534351145038168</prop>
<tuv xml:lang="en">
<seg>A primary course of 2-3 doses is usually given between two and twelve months of age, in accordance with the national vaccination schedule.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Prva terapija od dvije do tri doze obično se daje u dobi od dva do dvanaest mjeseci, u skladu s nacionalnim rasporedom cijepljenja.</seg>
</tuv>
</tu>
<tu tuid="339">
<prop type="lengthRatio">1.2419354838709677</prop>
<tuv xml:lang="en">
<seg>The most important way to prevent pertussis is through complete immunisation.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Najvažniji način sprječavanja hripavca je potpuno cijepljenje.</seg>
</tuv>
</tu>
<tu tuid="340">
<prop type="lengthRatio">1.065217391304348</prop>
<tuv xml:lang="en">
<seg>Complications include pneumonia, encephalopathy (a disease of the brain), seizures and even death.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Komplikacije uključuju upalu pluća, encefalopatiju (bolest mozga), konvulzije pa čak i smrt.</seg>
</tuv>
</tu>
<tu tuid="341">
<prop type="lengthRatio">1.0416666666666667</prop>
<tuv xml:lang="en">
<seg>The most severe forms of pertussis are in infants.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Najteži oblici hripavca javljaju se u dojenčadi.</seg>
</tuv>
</tu>
<tu tuid="342">
<prop type="lengthRatio">1.0423280423280423</prop>
<tuv xml:lang="en">
<seg>The vaccine for pertussis is usually given in combination with diphtheria and tetanus vaccination (often in combination also with poliomyelitis, Haemophilus influenzae and hepatitis B vaccination).</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Cjepivo protiv hripavca obično se daje u kombinaciji s cjepivima protiv difterije i tetanusa (često u kombinaciji i s cjepivima protiv dječje paralize, hemofilusa influence i hepatitisa B).</seg>
</tuv>
</tu>
<tu tuid="343">
<prop type="lengthRatio">0.8837209302325582</prop>
<tuv xml:lang="en">
<seg>In these groups, and in very young infants, pertussis is harder to diagnose.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>U tim skupinama, kao i u djece rane dojenačke dobi, hripavac je teže dijagnosticirati.</seg>
</tuv>
</tu>
<tu tuid="344">
<prop type="lengthRatio">1.03125</prop>
<tuv xml:lang="en">
<seg>In young infants the typical 'whoop' may never develop, and the coughing fits may be followed by brief periods when breathing stops.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>U dojenčadi se možda nikad neće razviti tipični „hrip", a nakon napada kašlja mogu slijediti kratka razdoblja prestanka disanja.</seg>
</tuv>
</tu>
<tu tuid="345">
<prop type="lengthRatio">0.9393939393939394</prop>
<tuv xml:lang="en">
<seg>How can pertussis be prevented?</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Kako se hripavac može spriječiti?</seg>
</tuv>
</tu>
<tu tuid="346">
<prop type="lengthRatio">0.9568345323741008</prop>
<tuv xml:lang="en">
<seg>In adults and older children, complications include inability to breathe for short periods, broken ribs, rectal prolapse and hernias.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>U odraslih osoba i veće djece komplikacije obuhvaćaju kratkotrajnu nemogućnost disanja, slomljena rebra, rektalni prolaps i herniju (kilu).</seg>
</tuv>
</tu>
<tu tuid="347">
<prop type="lengthRatio">0.872</prop>
<tuv xml:lang="en">
<seg>Initially, symptoms resemble those of a common cold (sneezing, runny nose, low-grade fever and a mild cough).</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Na početku simptomi nalikuju simptomima obične prehlade (kihanje, curenje iz nosa, malo povišena temperatura i blagi kašalj).</seg>
</tuv>
</tu>
<tu tuid="348">
<prop type="lengthRatio">1.125</prop>
<tuv xml:lang="en">
<seg>What is pertussis?</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Što je hripavac?</seg>
</tuv>
</tu>
<tu tuid="349">
<prop type="lengthRatio">1.064102564102564</prop>
<tuv xml:lang="en">
<seg>Pertussis is a highly infectious bacterial disease involving the lungs and airways.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Hripavac je vrlo zarazna bakterijska bolest koja zahvaća pluća i dišne putove.</seg>
</tuv>
</tu>
<tu tuid="350">
<prop type="lengthRatio">1.3461538461538463</prop>
<tuv xml:lang="en">
<seg>What are the symptoms of pertussis?</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Koji su simptomi hripavca?</seg>
</tuv>
</tu>
<tu tuid="351">
<prop type="lengthRatio">1.06993006993007</prop>
<tuv xml:lang="en">
<seg>Within two weeks, the cough becomes more severe and is characterized by episodes of numerous rapid coughs, followed by a crowing or high-pitched ‘whoop'.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>U sljedeća dva tjedna kašalj se pojačava, a za tu fazu tipični su brojni brzi udari kašlja nakon kojih slijedi glasan piskav udisaj ili „hrip".</seg>
</tuv>
</tu>
<tu tuid="352">
<prop type="lengthRatio">1.2033898305084745</prop>
<tuv xml:lang="en">
<seg>Anyone who is not vaccinated with the pertussis vaccine, or whose vaccination status is not up-to-date, is at risk of contracting the disease.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Svatko tko nije cijepljen protiv hripavca ili tko nije primio sve potrebne doze cjepiva može se zaraziti ovom bolešću.</seg>
</tuv>
</tu>
<tu tuid="353">
<prop type="lengthRatio">0.9659090909090909</prop>
<tuv xml:lang="en">
<seg>Antibiotics can be used to treat pertussis and prevent further spread of the disease.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Za liječenje hripavca i sprječavanje širenja bolesti mogu se upotrebljavati antibiotici.</seg>
</tuv>
</tu>
<tu tuid="354">
<prop type="lengthRatio">1.0</prop>
<tuv xml:lang="en">
<seg>What are the complications of pertussis?</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Koje su komplikacije izazvane hripavcem?</seg>
</tuv>
</tu>
<tu tuid="355">
<prop type="lengthRatio">1.375</prop>
<tuv xml:lang="en">
<seg>Some EU/EEA countries recommend boosters for adolescents, adults, and/or women during pregnancy, which also temporarily protects the baby once it is born.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>U nekim državama članicama EU-a/EGP-a preporučuje se docjepljivanje adolescenata, odraslih osoba i/ili trudnica.</seg>
</tuv>
</tu>
<tu tuid="356">
<prop type="lengthRatio">1.0909090909090908</prop>
<tuv xml:lang="en">
<seg>How is pertussis spread?</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Kako se hripavac širi?</seg>
</tuv>
</tu>
<tu tuid="357">
<prop type="lengthRatio">1.0416666666666667</prop>
<tuv xml:lang="en">
<seg>How is pertussis treated?</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Kako se hripavac liječi?</seg>
</tuv>
</tu>
<tu tuid="358">
<prop type="lengthRatio">1.09375</prop>
<tuv xml:lang="en">
<seg>It is also known as whooping cough.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Poznat je i pod imenom pertusis.</seg>
</tuv>
</tu>
<tu tuid="359">
<prop type="lengthRatio">0.8292682926829268</prop>
<tuv xml:lang="en">
<seg>Pertussis in unvaccinated infants or infants whose mother was unvaccinated can be particularly severe.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Hripavac može poprimiti posebno teške oblike u dojenčadi koja nije cijepljenja ili u dojenčadi čije majke nisu cijepljenje.</seg>
</tuv>
</tu>
<tu tuid="360">
<prop type="lengthRatio">1.275</prop>
<tuv xml:lang="en">
<seg>These episodes frequently end with the expulsion of a thick, clear mucous, often followed by vomiting.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Napadi kašlja često završavaju izbacivanjem guste, prozirne sluzi i povraćanjem.</seg>
</tuv>
</tu>
<tu tuid="361">
<prop type="lengthRatio">0.9540229885057471</prop>
<tuv xml:lang="en">
<seg>Pertussis is spread via airborne droplets produced when the infected person coughs.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Hripavac se širi zrakom u kapljicama koje nastaju kašljanjem i kihanjem zaražene osobe.</seg>
</tuv>
</tu>
<tu tuid="362">
<prop type="lengthRatio">1.1818181818181819</prop>
<tuv xml:lang="en">
<seg>Vaccination protects individuals against diseases that could have serious consequences for their health, for example:</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Cijepljenjem se osobe štiti od bolesti koje mogu imati ozbiljne posljedice za zdravlje, kao što su:</seg>
</tuv>
</tu>
<tu tuid="363">
<prop type="lengthRatio">0.9769230769230769</prop>
<tuv xml:lang="en">
<seg>pertussis (whooping cough) can be particularly serious in infants, causing coughing spells that may recur for up to two months.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>hripavac (pertussis), koji može biti posebno opasan za novorođenčad jer uzrokuje napade kašlja koji mogu trajati i do dva mjeseca.</seg>
</tuv>
</tu>
<tu tuid="364">
<prop type="lengthRatio">0.9900990099009901</prop>
<tuv xml:lang="en">
<seg>This list with examples includes diseases for which vaccines are included in the national immunisation programmes, and/or are given to persons considered to be at a higher risk of getting the disease.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Ovaj popis primjera obuhvaća bolesti protiv kojih je cjepivo uključeno u nacionalne programe cijepljenja, a također ga se može davati osobama za koje se smatra da su sklonije zarazi od određene bolesti.</seg>
</tuv>
</tu>
<tu tuid="365">
<prop type="lengthRatio">1.0851063829787233</prop>
<tuv xml:lang="en">
<seg>Complications include pneumonia, encephalopathy (a disease of the brain), seizures and even death (5).</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Komplikacije uključuju upalu pluća, encefalopatiju (bolest mozga), napadaje pa čak i smrt (5).</seg>
</tuv>
</tu>
<tu tuid="366">
<prop type="lengthRatio">1.0641711229946524</prop>
<tuv xml:lang="en">
<seg>almost 9 out of 10 babies born to mothers who had rubella in early pregnancy, will suffer from congenital rubella syndrome (with conditions such as deafness, cataracts and learning disabilities) (2);</seg>
</tuv>
<tuv xml:lang="hr">
<seg>gotovo 9 od 10 beba čije su majke preboljele rubeolu u ranoj trudnoći razvija sindrom kongenitalne rubeole (koji uključuje poremećaje poput gluhoće, katarakte i poteškoća pri učenju) (2);</seg>
</tuv>
</tu>
<tu tuid="367">
<prop type="lengthRatio">0.9903846153846154</prop>
<tuv xml:lang="en">
<seg>meningococcal disease kills 1 in 10 people affected, even with prompt diagnosis and treatment, while problems including neurological or hearing impairment and amputation occur in up to 20% of survivors (3);</seg>
</tuv>
<tuv xml:lang="hr">
<seg>meningokokna bolest, koja ubija svaku desetu oboljelu osobu, čak i uz brzo dijagnosticiranje i liječenje, dok su neurološki poremećaji, oštećenje sluha i amputacije zabilježeni kod 20 % preživjelih osoba (3);</seg>
</tuv>
</tu>
<tu tuid="368">
<prop type="lengthRatio">0.961038961038961</prop>
<tuv xml:lang="en">
<seg>diphtheria kills 1 in every 10 people who get it, even with treatment (1);</seg>
</tuv>
<tuv xml:lang="hr">
<seg>difterija, koja ubija svaku desetu oboljelu osobu, čak i nakon liječenja (1);</seg>
</tuv>
</tu>
<tu tuid="369">
<prop type="lengthRatio">0.97</prop>
<tuv xml:lang="en">
<seg>measles is highly contagious and 3 out of 10 people affected develop complications (4), which can include ear infection, diarrhoea, pneumonia and encephalitis (inflammation of the brain tissue);</seg>
</tuv>
<tuv xml:lang="hr">
<seg>ospice, koje su izuzetno zarazna bolest pri kojoj svaka treća oboljela osoba razvija komplikacije (4), koje mogu uključivati infekciju uha, proljev, upalu pluća i encefalitis (upalu moždanih stanica);</seg>
</tuv>
</tu>
<tu tuid="370">
<prop type="lengthRatio">0.8681318681318682</prop>
<tuv xml:lang="en">
<seg>(1) ECDC factsheet - Diphtheria: https://www.ecdc.europa.eu/en/diphtheria/facts</seg>
</tuv>
<tuv xml:lang="hr">
<seg>(1) Informativni sažetak ECDC-a - Difterija: https://www.ecdc.europa.eu/en/diphtheria/facts</seg>
</tuv>
</tu>
<tu tuid="371">
<prop type="lengthRatio">0.8651685393258427</prop>
<tuv xml:lang="en">
<seg>(5) ECDC factsheet - Pertussis: https://www.ecdc.europa.eu/en/pertussis/facts</seg>
</tuv>
<tuv xml:lang="hr">
<seg>(5) Informativni sažetak ECDC-a - Hripavac: https://www.ecdc.europa.eu/en/pertussis/facts</seg>
</tuv>
</tu>
<tu tuid="372">
<prop type="lengthRatio">0.889763779527559</prop>
<tuv xml:lang="en">
<seg>(2) ECDC factsheet - Congenital Rubella Syndrome: https://www.ecdc.europa.eu/en/congenital-rubella-syndrome/facts</seg>
</tuv>
<tuv xml:lang="hr">
<seg>(2) Informativni sažetak ECDC-a - Sindrom kongenitalne rubeole: https://www.ecdc.europa.eu/en/congenital-rubella-syndrome/facts</seg>
</tuv>
</tu>
<tu tuid="373">
<prop type="lengthRatio">0.9565217391304348</prop>
<tuv xml:lang="en">
<seg>It analyses many sources of data, including:</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Analizira brojne izvore podataka, uključujući:</seg>
</tuv>
</tu>
<tu tuid="374">
<prop type="lengthRatio">1.1549295774647887</prop>
<tuv xml:lang="en">
<seg>This ensures that any possible risks are detected and managed as soon as possible.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Time se osigurava što ranije otkrivanje i kontrola svih mogućih rizika.</seg>
</tuv>
</tu>
<tu tuid="375">
<prop type="lengthRatio">1.1318681318681318</prop>
<tuv xml:lang="en">
<seg>The process of monitoring the safety and managing the risks of medicines is called ‘pharmacovigilance'.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Postupak praćenja sigurnosti i upravljanja rizicima od lijekova zove se farmakovigilancija.</seg>
</tuv>
</tu>
<tu tuid="376">
<prop type="lengthRatio">1.0</prop>
<tuv xml:lang="en">
<seg>EMA checks new information on the safety of all vaccines available in Europe.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>EMA provjerava nove informacije o sigurnosti svih cjepiva dostupnih u Europi.</seg>
</tuv>
</tu>
<tu tuid="377">
<prop type="lengthRatio">1.4285714285714286</prop>
<tuv xml:lang="en">
<seg>reports from patients, parents and healthcare professionals;</seg>
</tuv>
<tuv xml:lang="hr">
<seg>izvješća bolesnika, roditelja i liječnika;</seg>
</tuv>
</tu>
<tu tuid="378">
<prop type="lengthRatio">0.7878787878787878</prop>
<tuv xml:lang="en">
<seg>For more information, see:</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Više informacija potražite ovdje:</seg>
</tuv>
</tu>
<tu tuid="379">
<prop type="lengthRatio">1.008</prop>
<tuv xml:lang="en">
<seg>For example, they can provide updated guidance to healthcare workers, or even restrict the use of a vaccine in certain groups.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Na primjer, izdaju ažurirane smjernice zdravstvenim radnicima, a ponekad ograničavaju primjenu cjepiva u određenim skupinama.</seg>
</tuv>
</tu>
<tu tuid="380">
<prop type="lengthRatio">0.9081632653061225</prop>
<tuv xml:lang="en">
<seg>Once a vaccine is approved for use, EU/EEA national authorities and the European Medicines Agency (EMA), continually monitor side effects in people who have received the vaccine.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Nakon što je cjepivo odobreno za primjenu, nacionalna nadležna tijela u državama EU-a / EGP-a i Europska agencija za lijekove (EMA), kontinuirano prate nuspojave kod osoba koje su primile cjepivo.</seg>
</tuv>
</tu>
<tu tuid="381">
<prop type="lengthRatio">0.7222222222222222</prop>
<tuv xml:lang="en">
<seg>information shared by other regulators.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>informacije koje razmjenjuju druga regulatorna tijela.</seg>
</tuv>
</tu>
<tu tuid="382">
<prop type="lengthRatio">1.0380952380952382</prop>
<tuv xml:lang="en">
<seg>EMA carefully assesses suspected side effects to determine if there is a causal link with the vaccine or not.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>EMA detaljno procjenjuje sumnje na nuspojave kako bi utvrdila postoji li uzročna veza sa cjepivom ili ne.</seg>
</tuv>
</tu>
<tu tuid="383">
<prop type="lengthRatio">1.1755725190839694</prop>
<tuv xml:lang="en">
<seg>Patients, healthcare professionals and pharmaceutical companies should report all suspected side effects to their national medicines regulatory authority.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Bolesnici, liječnici i farmaceutske tvrtke trebaju prijaviti sve sumnje na nuspojave nacionalnim regulatornim tijelima za lijekove.</seg>
</tuv>
</tu>
<tu tuid="384">
<prop type="lengthRatio">0.8176100628930818</prop>
<tuv xml:lang="en">
<seg>This helps to rule out the possibility that it was a coincidence or that it was caused by factors unrelated to the vaccine itself.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Tim se pristupom doprinosi isključivanju mogućnosti da se radilo o slučajnosti ili da su nuspojave uzrokovane čimbenicima koji nisu povezani sa samim cjepivom.</seg>
</tuv>
</tu>
<tu tuid="385">
<prop type="lengthRatio">1.1967213114754098</prop>
<tuv xml:lang="en">
<seg>These could be due to an illness or anxiety over being given the vaccine.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>One mogu biti posljedica bolesti ili stresa zbog cijepljenja.</seg>
</tuv>
</tu>
<tu tuid="386">
<prop type="lengthRatio">0.8873239436619719</prop>
<tuv xml:lang="en">
<seg>When needed, EMA and the other European regulators take action.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>EMA i druga europska regulatorna tijela poduzimaju mjere prema potrebi.</seg>
</tuv>
</tu>
<tu tuid="387">
<prop type="lengthRatio">1.0746268656716418</prop>
<tuv xml:lang="en">
<seg>Information on these reported suspected side effects is publicly available on the European database of suspected adverse drug reaction reports .</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Informacije o prijavljenim sumnjama na nuspojave javno su dostupne u europskoj bazi podataka za prijavu sumnji na nuspojave lijekova .</seg>
</tuv>
</tu>
<tu tuid="388">
<prop type="lengthRatio">1.0</prop>
<tuv xml:lang="en">
<seg>More information on how to report suspected side effects can be found in the prescribing information or package leaflet or the European database of suspected adverse drug reaction reports .</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Više informacija o izvješćivanju o sumnjama na nuspojave nalazi se u informacijama za propisivanje, u uputi o cjepivu ili u europskoj bazi podataka za prijavu sumnji na nuspojave lijekova .</seg>
</tuv>
</tu>
<tu tuid="389">
<prop type="lengthRatio">2.380952380952381</prop>
<tuv xml:lang="en">
<seg>Monitoring vaccine safety &amp; reporting side effects</seg>
</tuv>
<tuv xml:lang="hr">
<seg>klinička ispitivanja;</seg>
</tuv>
</tu>
<tu tuid="390">
<prop type="lengthRatio">0.9555555555555556</prop>
<tuv xml:lang="en">
<seg>the eyes become red and sensitive to light;</seg>
</tuv>
<tuv xml:lang="hr">
<seg>oči postanu crvene i osjetljive na svjetlost;</seg>
</tuv>
</tu>
<tu tuid="391">
<prop type="lengthRatio">1.1166666666666667</prop>
<tuv xml:lang="en">
<seg>on the third to seventh day, the temperature may reach up to 41 ⁰C;</seg>
</tuv>
<tuv xml:lang="hr">
<seg>između trećeg i sedmog dana temperatura može rasti do 41 ⁰C;</seg>
</tuv>
</tu>
<tu tuid="392">
<prop type="lengthRatio">1.0297029702970297</prop>
<tuv xml:lang="en">
<seg>It is estimated that one person with measles can infect on average between 12 and 18 unprotected people.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Procjenjuje se da jedna osoba zaražena ospicama može u prosjeku zaraziti 12 do 18 nezaštićenih osoba.</seg>
</tuv>
</tu>
<tu tuid="393">
<prop type="lengthRatio">1.0990990990990992</prop>
<tuv xml:lang="en">
<seg>The second dose can be given one month or more after the first dose, in accordance with the national vaccination schedule.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Druga se doza može dati mjesec dana nakon prve doze ili kasnije, u skladu s nacionalnim rasporedom cijepljenja.</seg>
</tuv>
</tu>
<tu tuid="394">
<prop type="lengthRatio">0.8860759493670886</prop>
<tuv xml:lang="en">
<seg>It is a serious disease that can lead to complications and even death.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>To je ozbiljna zarazna bolest koja može dovesti do komplikacija pa čak i smrti.</seg>
</tuv>
</tu>
<tu tuid="395">
<prop type="lengthRatio">1.0985915492957747</prop>
<tuv xml:lang="en">
<seg>The first dose is given between 10 and 18 months of age in European countries.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Prva se doza u europskim zemljama daje između 10. i 18. mjeseca života.</seg>
</tuv>
</tu>
<tu tuid="396">
<prop type="lengthRatio">1.1458333333333333</prop>
<tuv xml:lang="en">
<seg>There is no cure for SSPE and it always leads to death.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Za SSPE nema lijeka te on uvijek završava smrću.</seg>
</tuv>
</tu>
<tu tuid="397">
<prop type="lengthRatio">0.9829059829059829</prop>
<tuv xml:lang="en">
<seg>Symptoms include personality changes, gradual mental deterioration, muscle spasms and other neuromuscular symptoms.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Simptomi uključuju promjene ličnosti, postupnu mentalnu degradaciju, grčenje mišića i druge neuromuskularne simptome.</seg>
</tuv>
</tu>
<tu tuid="398">
<prop type="lengthRatio">1.1240875912408759</prop>
<tuv xml:lang="en">
<seg>The mortality rate for measles is 1-3 persons per 1 000 cases and highest in those younger than five years of age and among immunocompromised individuals.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Stopa smrtnosti zbog ospica jest 1 - 3 osobe na 1000 slučajeva i najviša je među djecom mlađom od pet godina i imunosuprimiranim osobama.</seg>
</tuv>
</tu>
<tu tuid="399">
<prop type="lengthRatio">0.9693877551020408</prop>
<tuv xml:lang="en">
<seg>a red rash lasting four to seven days begins on the face and then spreads over the entire body;</seg>
</tuv>
<tuv xml:lang="hr">
<seg>crveni osip koji traje četiri do sedam dana pojavljuje se na licu, a zatim širi po ostatku tijela;</seg>
</tuv>
</tu>
<tu tuid="400">
<prop type="lengthRatio">1.1162790697674418</prop>
<tuv xml:lang="en">
<seg>Virus-containing droplets can remain in the air for several hours and the virus remains infectious on contaminated surfaces for up to two hours.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Kapljice zaražene virusom mogu ostati u zraku i nekoliko sati, a virus ostaje zarazan na kontaminiranim površinama i do dva sata.</seg>
</tuv>
</tu>
<tu tuid="401">
<prop type="lengthRatio">1.132867132867133</prop>
<tuv xml:lang="en">
<seg>Such dose before the age of nine months is supplementary to the two doses included in the national vaccination programme, which are aimed to give full protection.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Ta doza prije dobi od devet mjeseci dodatna je doza dvjema dozama iz nacionalnog programa cijepljenja, čiji je cilj osiguranje potpune zaštite.</seg>
</tuv>
</tu>
<tu tuid="402">
<prop type="lengthRatio">0.9354838709677419</prop>
<tuv xml:lang="en">
<seg>How can measles be prevented?</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Kako se ospice mogu spriječiti?</seg>
</tuv>
</tu>
<tu tuid="403">
<prop type="lengthRatio">1.131578947368421</prop>
<tuv xml:lang="en">
<seg>There is no specific treatment for measles.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Ne postoji posebna terapija za ospice.</seg>
</tuv>
</tu>
<tu tuid="404">
<prop type="lengthRatio">0.9523809523809523</prop>
<tuv xml:lang="en">
<seg>Most people recover with supportive treatment, which can include hydration and anti-fever medicines.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Većina se osoba oporavi uz potpornu terapiju koja može uključivati hidrataciju i lijekove protiv vrućice.</seg>
</tuv>
</tu>
<tu tuid="405">
<prop type="lengthRatio">0.9739583333333334</prop>
<tuv xml:lang="en">
<seg>Infants from six to nine months of age who are in an area - or will be travelling to areas - with high risk of exposure to measles, should receive a supplementary dose of the MMR vaccine.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Dojenčad u dobi od šest do devet mjeseci starosti koja boravi na područjima s vrlo visokim rizikom od izloženosti ospicama ili će u ta područja putovati, treba dobiti dodatnu dozu cjepiva MMR.</seg>
</tuv>
</tu>
<tu tuid="406">
<prop type="lengthRatio">1.0</prop>
<tuv xml:lang="en">
<seg>Measles symptoms usually appear after 10-12 days of infection:</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Simptomi ospica obično se javljaju 10 do 12 dana nakon zaraze:</seg>
</tuv>
</tu>
<tu tuid="407">
<prop type="lengthRatio">1.0225563909774436</prop>
<tuv xml:lang="en">
<seg>The MMR (measles, mumps and rubella) vaccine is a combination vaccine that protects against measles, mumps and rubella (German measles).</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Cjepivo MMR (protiv ospica, zaušnjaka i rubeole) kombinirano je cjepivo koje štiti od ospica, zaušnjaka i rubeole (njemačkih ospica).</seg>
</tuv>
</tu>
<tu tuid="408">
<prop type="lengthRatio">1.0676691729323309</prop>
<tuv xml:lang="en">
<seg>A person who is infected may transmit measles even before the rash appears (usually 4 days), and for about 4 days after the rash has appeared.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Zaražena osoba može druge zaraziti ospicama čak i prije pojave osipa (obično četiri dana) i oko četiri dana nakon što se pojavi osip.</seg>
</tuv>
</tu>
<tu tuid="409">
<prop type="lengthRatio">0.8125</prop>
<tuv xml:lang="en">
<seg>Who is at risk of measles?</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Tko je izložen riziku od ospica?</seg>
</tuv>
</tu>
<tu tuid="410">
<prop type="lengthRatio">0.8522727272727273</prop>
<tuv xml:lang="en">
<seg>initial symptoms resemble a cold with a runny nose, cough and a mild fever;</seg>
</tuv>
<tuv xml:lang="hr">
<seg>početni simptomi slični su onima prehlade s curenjem iz nosa, kašljem i blagom vrućicom;</seg>
</tuv>
</tu>
<tu tuid="411">
<prop type="lengthRatio">0.9259259259259259</prop>
<tuv xml:lang="en">
<seg>small white spots may also appear on the gums and the inside of the cheeks.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>sitna bijela zrnca također se mogu javiti na desnima i s unutarnje strane obraza.</seg>
</tuv>
</tu>
<tu tuid="412">
<prop type="lengthRatio">1.0948275862068966</prop>
<tuv xml:lang="en">
<seg>Very rarely, a persistent measles virus infection can produce subacute sclerosing panencephalitis (SSPE), a disease in which nerves and brain tissue degenerate progressively and which is more likely to appear if measles infection occurs at a younger age.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Vrlo rijetko, perzistentna infekcija virusom ospica može uzrokovati subakutni sklerozirajući panencefalitis (SSPE), bolest kod koje živci i moždano tkivo progresivno degeneriraju te se češće javlja kod zaraze ospicama u mlađoj dobi.</seg>
</tuv>
</tu>
<tu tuid="413">
<prop type="lengthRatio">0.8981481481481481</prop>
<tuv xml:lang="en">
<seg>Pneumonia is a potential serious complication that has led to the death of some measles patients.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Upala pluća potencijalno je ozbiljna komplikacija koja je rezultirala smrću nekih osoba oboljelih od ospica.</seg>
</tuv>
</tu>
<tu tuid="414">
<prop type="lengthRatio">1.1590909090909092</prop>
<tuv xml:lang="en">
<seg>The only protection against measles is vaccination.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Jedina je zaštita protiv ospica cijepljenje.</seg>
</tuv>
</tu>
<tu tuid="415">
<prop type="lengthRatio">1.148936170212766</prop>
<tuv xml:lang="en">
<seg>Measles spreads easily among unvaccinated individuals.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Ospice se među necijepljenim osobama brzo šire.</seg>
</tuv>
</tu>
<tu tuid="416">
<prop type="lengthRatio">1.164179104477612</prop>
<tuv xml:lang="en">
<seg>Antibiotics are not effective against measles because it is caused by a virus.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Ospice se ne mogu liječiti antibioticima jer bolest uzrokuje virus.</seg>
</tuv>
</tu>
<tu tuid="417">
<prop type="lengthRatio">1.0207253886010363</prop>
<tuv xml:lang="en">
<seg>A variety of measures are employed to avoid the further spread of measles, such as quarantine from school or work for both the ill person and those close contacts with uncertain vaccination status.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Provodi se niz mjera za suzbijanje daljnjeg širenja ospica poput izostanka iz škole ili s posla i zaražene osobe i ostalih iz njegova okruženja, kao i osoba s nepotvrđenim statusom cijepljenja.</seg>
</tuv>
</tu>
<tu tuid="418">
<prop type="lengthRatio">1.0930232558139534</prop>
<tuv xml:lang="en">
<seg>About 1 measles patient in 1 000 develops inflammation of the brain tissue (encephalitis), a condition that results in permanent neurological disability in approximately one of four cases.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Otprilike jedna na 1000 osoba razvija upalu moždanih stanica (encefalitis), bolest čija je posljedica trajan neurološki invaliditet kod otprilike svakog četvrtog bolesnika.</seg>
</tuv>
</tu>
<tu tuid="419">
<prop type="lengthRatio">1.015267175572519</prop>
<tuv xml:lang="en">
<seg>SSPE typically appears several years after the affected patient had measles; on average it is seen 7 to 10 years after the infection.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>SSPE se obično javlja nekoliko godina nakon što je osoba preboljela ospice, u prosjeku sedam do deset godina nakon zaraze ospicama.</seg>
</tuv>
</tu>
<tu tuid="420">
<prop type="lengthRatio">0.9141104294478528</prop>
<tuv xml:lang="en">
<seg>Some vaccine recipients develop a non-infectious mild measles-like rash, typically 7 - 14 days after vaccination, which disappears within 1 - 3 days.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Kod nekih cijepljenih osoba razvija se neinfektivni blagi osip nalik ospicama, u pravilu 7 do 14 dana nakon cijepljenja, koji nestaje u roku od jednog do tri dana.</seg>
</tuv>
</tu>
<tu tuid="421">
<prop type="lengthRatio">1.0594059405940595</prop>
<tuv xml:lang="en">
<seg>Measles is a highly contagious viral disease that can be contracted at any age, and that can spread widely.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Ospice su vrlo zarazna virusna bolest od koje se može oboljeti u bilo kojoj dobi i koja se brzo širi.</seg>
</tuv>
</tu>
<tu tuid="422">
<prop type="lengthRatio">1.0816326530612246</prop>
<tuv xml:lang="en">
<seg>However, antibiotics are often used to treat complications with bacterial infections that can develop because of measles, such as pneumonia and ear infections.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Međutim, antibiotici se često primjenjuju za liječenje komplikacija ospica poput bakterijskih infekcija koje uključuju upalu pluća i infekcije uha.</seg>
</tuv>
</tu>
<tu tuid="423">
<prop type="lengthRatio">1.375</prop>
<tuv xml:lang="en">
<seg>What are the symptoms of measles?</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Koji su simptomi ospica?</seg>
</tuv>
</tu>
<tu tuid="424">
<prop type="lengthRatio">1.3571428571428572</prop>
<tuv xml:lang="en">
<seg>What are the complications of measles?</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Koje su komplikacije ospica?</seg>
</tuv>
</tu>
<tu tuid="425">
<prop type="lengthRatio">0.635593220338983</prop>
<tuv xml:lang="en">
<seg>30% of children and adults infected with measles can develop complications.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Komplikacije se mogu razviti kod 30 % djece i odraslih zaraženih ospicama te mogu uključivati infekcije uha i proljev.</seg>
</tuv>
</tu>
<tu tuid="426">
<prop type="lengthRatio">1.1428571428571428</prop>
<tuv xml:lang="en">
<seg>What is measles?</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Što su ospice?</seg>
</tuv>
</tu>
<tu tuid="427">
<prop type="lengthRatio">1.2409638554216869</prop>
<tuv xml:lang="en">
<seg>The measles virus is spread via airborne droplets produced when the infected person coughs and sneezes.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Virus ospica širi se zrakom kapljicama koje iskašljavaju ili izdišu zaražene osobe.</seg>
</tuv>
</tu>
<tu tuid="428">
<prop type="lengthRatio">1.1</prop>
<tuv xml:lang="en">
<seg>How is measles spread?</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Kako se ospice šire?</seg>
</tuv>
</tu>
<tu tuid="429">
<prop type="lengthRatio">0.7848101265822784</prop>
<tuv xml:lang="en">
<seg>The MMR vaccine may be given earlier in life during outbreaks.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Tijekom izbijanja epidemija ospica cjepivo MMR može se davati i u ranijoj dobi.</seg>
</tuv>
</tu>
<tu tuid="430">
<prop type="lengthRatio">0.7228915662650602</prop>
<tuv xml:lang="en">
<seg>Pneumonia is the most common cause of measles-related death.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Upala pluća koja je rezultirala smrću najčešća je komplikacija uzrokovana ospicama.</seg>
</tuv>
</tu>
<tu tuid="431">
<prop type="lengthRatio">1.0454545454545454</prop>
<tuv xml:lang="en">
<seg>How is measles treated?</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Kako se ospice liječe?</seg>
</tuv>
</tu>
<tu tuid="432">
<prop type="lengthRatio">1.125</prop>
<tuv xml:lang="en">
<seg>Anyone who is not vaccinated against measles or who has not had the disease is at risk of getting measles at any age.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Riziku od ospica izložene su osobe svih dobi koje nisu cijepljenje protiv ospica ili ih nisu preboljele.</seg>
</tuv>
</tu>
<tu tuid="433">
<prop type="lengthRatio">1.0</prop>
<tuv xml:lang="en">
<seg>It provides options for the user to filter information by criteria such as disease and time-period.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Korisnicima nudi mogućnost filtriranja informacija prema kriterijima kao što su bolest i razdoblje.</seg>
</tuv>
</tu>
<tu tuid="434">
<prop type="lengthRatio">1.0175438596491229</prop>
<tuv xml:lang="en">
<seg>The data is based on information submitted and verified by Member States through ECDC's disease surveillance system.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Temelje se na informacijama koje su dostavile i potvrdile države članice putem ECDC-ova sustava za nadzor bolesti.</seg>
</tuv>
</tu>
<tu tuid="435">
<prop type="lengthRatio">0.94375</prop>
<tuv xml:lang="en">
<seg>The ECDC Surveillance Atlas of Infectious Diseases also provides data on other vaccine-preventable diseases, such as diphtheria, pertussis and rubella.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>ECDC-ov atlas za nadzor zaraznih bolesti sadržava podatke i o drugim bolestima koje je moguće spriječiti cijepljenjem, kao što su difterija, hripavac i rubeola.</seg>
</tuv>
</tu>
<tu tuid="436">
<prop type="lengthRatio">0.8275862068965517</prop>
<tuv xml:lang="en">
<seg>Below are the most recent data on measles outbreaks in EU Member States.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>U nastavku su prikazani najnoviji podatci o izbijanju ospica u državama članicama EU-a.</seg>
</tuv>
</tu>
<tu tuid="437">
<prop type="lengthRatio">1.0</prop>
<tuv xml:lang="en">
<seg>Situation of measles in the EU</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Stanje u EU-u u pogledu ospica</seg>
</tuv>
</tu>
<tu tuid="438">
<prop type="lengthRatio">1.0</prop>
<tuv xml:lang="en">
<seg>Serious side effects are very rare.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Ozbiljne nuspojave jako su rijetke.</seg>
</tuv>
</tu>
<tu tuid="439">
<prop type="lengthRatio">1.121212121212121</prop>
<tuv xml:lang="en">
<seg>The first vaccine was developed in the 18th century in the United Kingdom.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Prvo cjepivo razvijeno je u 18. stoljeću u Ujedinjenoj Kraljevini.</seg>
</tuv>
</tu>
<tu tuid="440">
<prop type="lengthRatio">0.8089887640449438</prop>
<tuv xml:lang="en">
<seg>The last known naturally occurring case was recorded in 1977 in Somalia.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Posljednji poznati slučaj prirodne pojave velikih boginja zabilježen je 1977. u Somaliji.</seg>
</tuv>
</tu>
<tu tuid="441">
<prop type="lengthRatio">1.0833333333333333</prop>
<tuv xml:lang="en">
<seg>The vaccine is continuously monitored to ensure it remains safe and effective.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Cjepivo se neprestano prati kako bi i nadalje bilo sigurno i učinkovito.</seg>
</tuv>
</tu>
<tu tuid="442">
<prop type="lengthRatio">1.03125</prop>
<tuv xml:lang="en">
<seg>They also help to prevent the spread of diseases in the community.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Osim toga pomažu i kod sprječavanja širenja bolesti u zajednici.</seg>
</tuv>
</tu>
<tu tuid="443">
<prop type="lengthRatio">0.7532467532467533</prop>
<tuv xml:lang="en">
<seg>They mainly target diseases caused by viruses or bacteria.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Uglavnom se upotrebljavaju protiv bolesti uzrokovanih virusima i bakterijama.</seg>
</tuv>
</tu>
<tu tuid="444">
<prop type="lengthRatio">1.089171974522293</prop>
<tuv xml:lang="en">
<seg>The scientific experts evaluating vaccines always consider the benefits and any potential risks very carefully, in particular because vaccines are given to healthy people.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Znanstvenici koji ocjenjuju cjepiva uvijek vrlo pažljivo razmatraju koristi i sve potencijalne rizike, osobito zbog toga što se cjepivo daje zdravim ljudima.</seg>
</tuv>
</tu>
<tu tuid="445">
<prop type="lengthRatio">1.0707964601769913</prop>
<tuv xml:lang="en">
<seg>As with any medicine, some people may experience side effects from a vaccine, but these are usually mild and short-lived.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Kao i kod svakog lijeka kod nekih osoba mogu nastupiti nuspojave cjepiva, ali one su obično blage i kratkotrajne.</seg>
</tuv>
</tu>
<tu tuid="446">
<prop type="lengthRatio">0.9215686274509803</prop>
<tuv xml:lang="en">
<seg>Only then, after approval, can a vaccine be manufactured, marketed and used to protect people.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Tek nakon odobrenja cjepivo se može proizvoditi, stavljati u promet i upotrebljavati za zaštitu ljudi.</seg>
</tuv>
</tu>
<tu tuid="447">
<prop type="lengthRatio">0.9459459459459459</prop>
<tuv xml:lang="en">
<seg>They can include mild fever, or pain or redness at the injection site.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>To mogu biti blaga vrućica, bol ili crvenilo na mjestu primjene injekcije.</seg>
</tuv>
</tu>
<tu tuid="448">
<prop type="lengthRatio">0.7717391304347826</prop>
<tuv xml:lang="en">
<seg>Before any new vaccine can be used, it has to undergo rigorous testing.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Prije nego što se bilo koje novo cjepivo počne primjenjivati, mora proći stroga ispitivanja.</seg>
</tuv>
</tu>
<tu tuid="449">
<prop type="lengthRatio">1.1140350877192982</prop>
<tuv xml:lang="en">
<seg>Vaccines work by ‘teaching' a person's immune system (the body's natural defences) to defend itself against a specific disease.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Cjepiva djeluju tako što uče imunosni sustav (prirodnoj obrani tijela) osobe kako se obraniti od određene bolesti.</seg>
</tuv>
</tu>
<tu tuid="450">
<prop type="lengthRatio">1.072</prop>
<tuv xml:lang="en">
<seg>This evaluation needs to show that a vaccine's benefits in protecting people against diseases are far greater than any potential risk.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Ocjenjivanjem je potrebo utvrditi da su koristi cjepiva za zaštitu ljudi od bolesti daleko veće od svih potencijalnih rizika.</seg>
</tuv>
</tu>
<tu tuid="451">
<prop type="lengthRatio">1.0476190476190477</prop>
<tuv xml:lang="en">
<seg>Recently, a vaccine was developed against Ebola virus disease, and research is underway on vaccines to protect against human immunodeficiency virus (HIV).</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Nedavno je razvijeno cjepivo protiv virusne bolesti ebole, a u tijeku je istraživanje cjepiva za zaštitu od virusa humane imunodeficijencije (HIV).</seg>
</tuv>
</tu>
<tu tuid="452">
<prop type="lengthRatio">1.0681818181818181</prop>
<tuv xml:lang="en">
<seg>Nowadays, there are vaccines for many diseases.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Danas postoje cjepiva protiv mnogih bolesti.</seg>
</tuv>
</tu>
<tu tuid="453">
<prop type="lengthRatio">1.2247191011235956</prop>
<tuv xml:lang="en">
<seg>Vaccines are used worldwide as a highly effective way to protect people from contracting infectious diseases.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Cjepiva se diljem svijeta upotrebljavaju kao vrlo učinkovita zaštita od zaraznih bolesti.</seg>
</tuv>
</tu>
<tu tuid="454">
<prop type="lengthRatio">0.9117647058823529</prop>
<tuv xml:lang="en">
<seg>Research is ongoing to develop vaccines against more diseases.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>U tijeku su istraživanja za razvoj cjepiva protiv još nekih bolesti.</seg>
</tuv>
</tu>
<tu tuid="455">
<prop type="lengthRatio">0.8387096774193549</prop>
<tuv xml:lang="en">
<seg>It was a vaccine against smallpox, a deadly disease.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Bilo je to cjepivo protiv velikih boginja, smrtonosne bolesti.</seg>
</tuv>
</tu>
<tu tuid="456">
<prop type="lengthRatio">1.2105263157894737</prop>
<tuv xml:lang="en">
<seg>Benefits of vaccinating</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Činjenice o cjepivu</seg>
</tuv>
</tu>
<tu tuid="457">
<prop type="lengthRatio">0.9631336405529954</prop>
<tuv xml:lang="en">
<seg>The vaccine can only be approved for use in the European Union (EU) and European Economic Area (EEA) after a scientific evaluation of the results of these tests to ensure its quality, safety and effectiveness.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Tek nakon znanstvene ocjene rezultata tih ispitivanja kojima se osigurava kvaliteta, sigurnost i učinkovitost cjepiva, ono može biti odobreno za primjenu u Europskoj uniji (EU) i Europskom gospodarskom prostoru (EGP).</seg>
</tuv>
</tu>
<tu tuid="458">
<prop type="lengthRatio">0.5087719298245614</prop>
<tuv xml:lang="en">
<seg>Safety, quality and standards</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Praćenje sigurnosti cjepiva i izvješćivanje o nuspojavama</seg>
</tuv>
</tu>
<tu tuid="459">
<prop type="lengthRatio">0.8625</prop>
<tuv xml:lang="en">
<seg>Smallpox is now eradicated worldwide in humans thanks to vaccination.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Zahvaljujući cijepljenju velike boginje u ljudi iskorijenjene su diljem svijeta.</seg>
</tuv>
</tu>
<tu tuid="460">
<prop type="lengthRatio">0.8857142857142857</prop>
<tuv xml:lang="en">
<seg>Twitter Facebook Linked In Mail</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Odobrenje cjepiva u Europskoj uniji</seg>
</tuv>
</tu>
<tu tuid="461">
<prop type="lengthRatio">1.0</prop>
<tuv xml:lang="en">
<seg>In some countries such recommendations are done at state or regional level.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>U nekim se zemljama te preporuke daju na razini saveznih država ili regija.</seg>
</tuv>
</tu>
<tu tuid="462">
<prop type="lengthRatio">1.0434782608695652</prop>
<tuv xml:lang="en">
<seg>Some vaccines are not part of routine vaccination schedules but are targeted at specific groups.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Neka cjepiva nisu dio rutinskih programa cijepljenja, već su namijenjena posebnim skupinama.</seg>
</tuv>
</tu>
<tu tuid="463">
<prop type="lengthRatio">0.9553571428571429</prop>
<tuv xml:lang="en">
<seg>In addition, vaccines to protect against specific diseases are sometimes recommended for ‘high-risk' groups, such as people with long-term health conditions or people planning to travel to other parts of the world.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Osim toga, cjepiva koja štite od određenih bolesti katkad se preporučuju za skupine izložene „visokom riziku", kao što su osobe s dugotrajnim zdravstvenim problemima ili osobe koji planiraju putovati u druge krajeve svijeta.</seg>
</tuv>
</tu>
<tu tuid="464">
<prop type="lengthRatio">0.8571428571428571</prop>
<tuv xml:lang="en">
<seg>Decisions on vaccines in use in different European countries</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Odluke o cjepivima koja se primjenjuju u različitim europskim zemljama</seg>
</tuv>
</tu>
<tu tuid="465">
<prop type="lengthRatio">1.0202702702702702</prop>
<tuv xml:lang="en">
<seg>Healthcare professionals (e.g. doctors, nurses) have a role in ensuring that patients in their care receive the recommended vaccines at the right time.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Uloga je zdravstvenih radnika (npr. liječnika i medicinskih sestara) zajamčiti da pacijenti u njihovoj skrbi pravovremeno prime preporučena cjepiva.</seg>
</tuv>
</tu>
<tu tuid="466">
<prop type="lengthRatio">1.0390625</prop>
<tuv xml:lang="en">
<seg>Vaccines are recommended for different age groups, often for infants and children, but also for teenagers, adults and elderly people.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Cjepiva se preporučuju za različite dobne skupine, često za novorođenčad i djecu, ali i za adolescente, odrasle i starije osobe.</seg>
</tuv>
</tu>
<tu tuid="467">
<prop type="lengthRatio">1.0130718954248366</prop>
<tuv xml:lang="en">
<seg>For example, people who travel to regions where certain infectious diseases circulate such as yellow fever and typhoid fever may need to have vaccinations.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Primjerice, osobe koje putuju u područja u kojima kolaju određene zarazne bolesti, poput žute groznice ili tifusne groznice, možda će se morati cijepiti.</seg>
</tuv>
</tu>
<tu tuid="468">
<prop type="lengthRatio">1.488888888888889</prop>
<tuv xml:lang="en">
<seg>They also provide recommendations for people with chronic diseases.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Usto, izdaju preporuke za kronične bolesnike.</seg>
</tuv>
</tu>
<tu tuid="469">
<prop type="lengthRatio">0.9514563106796117</prop>
<tuv xml:lang="en">
<seg>This is based on local conditions, such as how common the disease is, as well as economic factors.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>To ovisi o lokalnim uvjetima, kao što su učestalost određene bolesti, ali i o gospodarskim čimbenicima.</seg>
</tuv>
</tu>
<tu tuid="470">
<prop type="lengthRatio">0.7627118644067796</prop>
<tuv xml:lang="en">
<seg>Some countries require proof of certain vaccinations before granting entry to the country.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Neke zemlje zahtijevaju dokaz o cijepljenju protiv određenih bolesti prije nego što putnicima dopuste ulazak u zemlju.</seg>
</tuv>
</tu>
<tu tuid="471">
<prop type="lengthRatio">1.0</prop>
<tuv xml:lang="en">
<seg>Sometimes, more than one vaccine may be given at once to protect against several infectious diseases.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Katkad je moguće dati više cjepiva odjednom kako bi se postigla zaštita od nekoliko zaraznih bolesti.</seg>
</tuv>
</tu>
<tu tuid="472">
<prop type="lengthRatio">0.8387096774193549</prop>
<tuv xml:lang="en">
<seg>Combined use of vaccines is well established and based on scientific studies on its benefits and safety.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Kombinirana primjena cjepiva uvriježena je praksa i temelji se na znanstvenim istraživanjima o koristi i sigurnosti cjepiva.</seg>
</tuv>
</tu>
<tu tuid="473">
<prop type="lengthRatio">1.1153846153846154</prop>
<tuv xml:lang="en">
<seg>The main purpose of this website is to provide accurate, objective, up-to-date evidence on vaccines and vaccination.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Osnovna je svrha ovog mrežnog mjesta pružiti točne, objektivne i ažurne podatke o cjepivu i cijepljenju.</seg>
</tuv>
</tu>
<tu tuid="474">
<prop type="lengthRatio">1.1695906432748537</prop>
<tuv xml:lang="en">
<seg>Each factsheet provides key facts about a disease, with an overview of the symptoms, complications, how the disease spreads, who is at risk, how the disease can be prevented and how it can be treated.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Svaki članak sadrži ključne činjenice o bolesti s informacijama o simptomima, komplikacijama, načinu širenja, ugroženim skupinama, sprječavanju bolesti i načinu liječenja.</seg>
</tuv>
</tu>
<tu tuid="475">
<prop type="lengthRatio">0.9716312056737588</prop>
<tuv xml:lang="en">
<seg>Most national vaccination programmes in the EU/EEA include vaccines for up to twenty diseases which are given to people at specific ages.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Većina nacionalnih programa cijepljenja u EU-u/EGP-u obuhvaća cjepiva protiv najviše dvadeset bolesti koja se daju u određenoj životnoj dobi.</seg>
</tuv>
</tu>
<tu tuid="476">
<prop type="lengthRatio">1.0229885057471264</prop>
<tuv xml:lang="en">
<seg>Some vaccines protect against only one disease, but others protect against more than one.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Pojedina cjepiva štite od samo jedne bolesti, dok druga cjepiva štite od nekoliko njih.</seg>
</tuv>
</tu>
<tu tuid="477">
<prop type="lengthRatio">1.1633986928104576</prop>
<tuv xml:lang="en">
<seg>Vaccination also reduces the risk of spreading the diseases among family members, school mates or colleagues, friends and neighbours, as well as to other people in the community.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Cijepljenjem se smanjuje rizik od širenja bolesti među članovima obitelji, učenicima ili kolegama, prijateljima i susjedima i drugim ljudima u zajednici.</seg>
</tuv>
</tu>
<tu tuid="478">
<prop type="lengthRatio">0.9649122807017544</prop>
<tuv xml:lang="en">
<seg>To learn more about the diseases that can be prevented by vaccination, consult the factsheets available below.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Da biste saznali više o bolestima koje se mogu spriječiti cijepljenjem, pročitajte informativne članke u nastavku.</seg>
</tuv>
</tu>
<tu tuid="479">
<prop type="lengthRatio">0.9712643678160919</prop>
<tuv xml:lang="en">
<seg>For more information about national vaccination programmes, see the ECDC vaccine scheduler and visit the official websites on immunisation of the EU/EEA countries here .</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Više informacija o nacionalnim programima cijepljenja potražite u Kalendaru cijepljenja ECDC-a , a službene mrežne stranice zemalja EU-a/EGP-a o imunizaciji posjetite ovdje .</seg>
</tuv>
</tu>
<tu tuid="480">
<prop type="lengthRatio">0.7295597484276729</prop>
<tuv xml:lang="en">
<seg>National vaccination schedules in EU/EEA countries recommend vaccines at specific ages and for specific populations.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>U okviru svojih nacionalnih programa cijepljenja države na području EU-a/EGP-a preporučuju cjepiva u određenoj životnoj dobi i za određene dijelove populacije.</seg>
</tuv>
</tu>
<tu tuid="481">
<prop type="lengthRatio">1.0825688073394495</prop>
<tuv xml:lang="en">
<seg>Thanks to vaccination, people can be protected against diseases that could have serious consequences for their health.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Zahvaljujući cijepljenju, ljudi se mogu zaštititi od bolesti koje mogu imati ozbiljne posljedice za zdravlje.</seg>
</tuv>
</tu>
<tu tuid="482">
<prop type="lengthRatio">0.8895705521472392</prop>
<tuv xml:lang="en">
<seg>Some vaccine recipients develop a non-infectious mild measles-like rash, typically 7-14 days after vaccination, which disappears within 1-3 days.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Kod nekih cijepljenih osoba razvija se neinfektivni blagi osip nalik ospicama, u pravilu 7 do 14 dana nakon cijepljenja, koji nestaje u roku od jednog do tri dana.</seg>
</tuv>
</tu>
<tu tuid="483">
<prop type="lengthRatio">1.1568627450980393</prop>
<tuv xml:lang="en">
<seg>Nowadays, several diseases can be prevented by vaccination.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Cijepljenjem danas možemo spriječiti razne bolesti.</seg>
</tuv>
</tu>
<tu tuid="484">
<prop type="lengthRatio">0.9125</prop>
<tuv xml:lang="en">
<seg>Factsheets of five vaccine- preventable diseases are currently available.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Dosad smo objavili pet članaka o bolestima koje se mogu spriječiti cijepljenjem.</seg>
</tuv>
</tu>
<tu tuid="485">
<prop type="lengthRatio">0.95</prop>
<tuv xml:lang="en">
<seg>What are the complications of measles?</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Koje su komplikacije izazvane hripavcem?</seg>
</tuv>
</tu>
<tu tuid="486">
<prop type="lengthRatio">0.9915254237288136</prop>
<tuv xml:lang="en">
<seg>Anyone who is not vaccinated against measles or who has not had the disease is at risk of getting measles at any age.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Svatko tko nije cijepljen protiv hripavca ili tko nije primio sve potrebne doze cjepiva može se zaraziti ovom bolešću.</seg>
</tuv>
</tu>
<tu tuid="487">
<prop type="lengthRatio">0.46629213483146065</prop>
<tuv xml:lang="en">
<seg>Vaccination can eliminate diseases or reduce the number of new cases significantly.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>To je poznato pod nazivom „kolektivna imunost" (koja se ponekad još naziva i „imunost krda") Cijepljenjem je moguće iskorijeniti bolesti ili znatno smanjiti broj novih slučajeva.</seg>
</tuv>
</tu>
<tu tuid="488">
<prop type="lengthRatio">0.5253456221198156</prop>
<tuv xml:lang="en">
<seg>Information and links to the VSN member websites is available here: https://www.vaccinesafetynet.org/vsn/network .</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Ako želite više informacija o toj mreži, posjetite: https://vaccinesafetynet.org . Informacije o članicama mreže VSN i poveznice na njihova mrežna mjesta dostupne su ovdje: https://www.vaccinesafetynet.org/vsn/network</seg>
</tuv>
</tu>
<tu tuid="489">
<prop type="lengthRatio">0.9803921568627451</prop>
<tuv xml:lang="en">
<seg>More factsheets will be included at a later stage.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>S vremenom ćemo dodavati članke o drugim bolestima.</seg>
</tuv>
</tu>
<tu tuid="490">
<prop type="lengthRatio">0.7045454545454546</prop>
<tuv xml:lang="en">
<seg>Twitter Facebook Linked In Mail</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Europski portal za informacije o cijepljenju</seg>
</tuv>
</tu>
<tu tuid="491">
<prop type="lengthRatio">1.0357142857142858</prop>
<tuv xml:lang="en">
<seg>Safety, quality and standards</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Sigurnost, kvaliteta i norme</seg>
</tuv>
</tu>
<tu tuid="492">
<prop type="lengthRatio">1.0</prop>
<tuv xml:lang="en">
<seg>Human papillomavirus (HPV)</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Humani papilomavirus (HPV)</seg>
</tuv>
</tu>
<tu tuid="493">
<prop type="lengthRatio">1.2222222222222223</prop>
<tuv xml:lang="en">
<seg>The Vaccine Safety Net</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Vaccine Safety Net</seg>
</tuv>
</tu>
<tu tuid="494">
<prop type="lengthRatio">1.2820512820512822</prop>
<tuv xml:lang="en">
<seg>Source: Plotkin S, Orenstein W, Offit P. Vaccines.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Izvor: Plotkin S, Orenstein W, Offit P.</seg>
</tuv>
</tu>
<tu tuid="495">
<prop type="lengthRatio">0.8645833333333334</prop>
<tuv xml:lang="en">
<seg>The Commission is divided into departments that develop policies in specific areas.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Komisija je organizirana na temelju glavnih uprava koje razvijaju politiku za određena područja.</seg>
</tuv>
</tu>
<tu tuid="496">
<prop type="lengthRatio">1.0909090909090908</prop>
<tuv xml:lang="en">
<seg>What is HPV?</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Što je HPV?</seg>
</tuv>
</tu>
<tu tuid="497">
<prop type="lengthRatio">1.035294117647059</prop>
<tuv xml:lang="en">
<seg>A vaccine may be contraindicated for certain people, meaning they should not receive it.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Kod nekih osoba cjepivo može biti kontraindicirano, što znači da ga ne smiju primiti.</seg>
</tuv>
</tu>
<tu tuid="498">
<prop type="lengthRatio">1.1181102362204725</prop>
<tuv xml:lang="en">
<seg>Cervical cancer (cancer of the neck of the womb) is the most common cancer after breast cancer to affect women aged 15-44 years in Europe (1).</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Rak grlića maternice najčešća je vrsta raka, nakon raka dojke, od koje obolijevaju žene u Europi u dobi od 15 do 44 godine (1).</seg>
</tuv>
</tu>
<tu tuid="499">
<prop type="lengthRatio">1.0666666666666667</prop>
<tuv xml:lang="en">
<seg>What is rubella?</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Što je rubeola?</seg>
</tuv>
</tu>
<tu tuid="500">
<prop type="lengthRatio">0.8513513513513513</prop>
<tuv xml:lang="en">
<seg>The initiative aims to tackle vaccine hesitancy, improve coordination on vaccine procurement, support research and innovation, and strengthen EU cooperation on vaccine-preventable diseases.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Cilj je inicijative odgovoriti na oklijevanje s cijepljenjem, poboljšati koordinaciju u nabavi cjepiva, podržati istraživanje i razvoj te ojačati suradnju unutar EU-a u pogledu bolesti koje se mogu spriječiti cijepljenjem.</seg>
</tuv>
</tu>
<tu tuid="501">
<prop type="lengthRatio">0.8507462686567164</prop>
<tuv xml:lang="en">
<seg>Information and links to the VSN member websites is available here: https://www.vaccinesafetynet.org/vsn/network .</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Informacije o članicama mreže VSN i poveznice na njihova mrežna mjesta dostupne su ovdje: https://www.vaccinesafetynet.org/vsn/network</seg>
</tuv>
</tu>
<tu tuid="502">
<prop type="lengthRatio">1.0666666666666667</prop>
<tuv xml:lang="en">
<seg>The ‘high risk' HPV types can also cause anal and genital cancers, and some cancers of the head and neck, in both men and women.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>„Visokorizične" vrste HPV-a mogu uzrokovati i rak anusa i genitalija te neke vrste raka glave i vrata, neovisno o spolu.</seg>
</tuv>
</tu>
<tu tuid="503">
<prop type="lengthRatio">1.1827956989247312</prop>
<tuv xml:lang="en">
<seg>Possible contraindications should be always discussed with the healthcare provider before receiving a vaccine.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Prije cijepljenja uvijek se potrebno posavjetovati s liječnikom oko mogućih kontraindikacija.</seg>
</tuv>
</tu>
<tu tuid="504">
<prop type="lengthRatio">0.926829268292683</prop>
<tuv xml:lang="en">
<seg>For more information about the network visit: https://vaccinesafetynet.org .</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Ako želite više informacija o toj mreži, posjetite: https://vaccinesafetynet.org .</seg>
</tuv>
</tu>
<tu tuid="505">
<prop type="lengthRatio">1.4285714285714286</prop>
<tuv xml:lang="en">
<seg>What are the complications of pertussis?</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Koje su komplikacije ospica?</seg>
</tuv>
</tu>
<tu tuid="506">
<prop type="lengthRatio">1.0</prop>
<tuv xml:lang="en">
<seg>How is measles spread?</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Kako se hripavac širi?</seg>
</tuv>
</tu>
<tu tuid="507">
<prop type="lengthRatio">0.9583333333333334</prop>
<tuv xml:lang="en">
<seg>How is measles treated?</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Kako se hripavac liječi?</seg>
</tuv>
</tu>
<tu tuid="508">
<prop type="lengthRatio">0.972027972027972</prop>
<tuv xml:lang="en">
<seg>Medicines regulatory authorities can carry out inspections to make sure that the information the vaccine developer provides is trustworthy.</seg>
</tuv>
<tuv xml:lang="hr">
<seg>Mogu provoditi i ispitivanja kako bi bila sigurna da su serije cjepiva stavljene u promet odgovarajuće kvalitete te da su ispravno proizvedene.</seg>
</tuv>
</tu>
</body>
</tmx>